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OBJECTIVES: 
This study was planned to assess the clinical utility of TWEAK in the care and the management of patients with 
lupus nephritis in children with systemic lupus erythematosus. The primary objective was to assess the 
correlation of urinary TWEAK level with renal SLEDAI score and also to assess the ability of urinary TWEAK 
levels to differentiate the class of lupus nephritis as per the histopathological findings (renal biopsy report). 
METHODS: 
The prospective study was conducted over a period of 11 months (September 2014 – October 2015) in the 
department of Child Health, Christian Medical College, Vellore, a tertiary care centre in South India. Children 
with SLE who fulfilled the inclusion criteria were further subdivided based on biopsy report and renal SLEDAI 
scores into the following groups:SLE with lupus nephritis, SLE without lupus nephritis,disease controls which  
included children with other autoimmune and renal disease and healthy controls which included healthy children 
with normal baseline parameters. The primary outcome assessed was the urinary TWEAK levels which was 
done using the TWEAK ELISA ,which is a quantitative competitive immunoassay .Data analysis was done by 
means of student’s t test, the chi – square test or Mann- Whitney U test, as appropriate. Pearson’s correlation 
with Anova’s statistical methods was used to ascertain the significance of statistical correlation. 
RESULTS 
1) The mean level of Urinary Tweak levels was 3.49 ± 2.29 ng/ml, ranging from 0.02 to 10.35 ng/ml. The 
urinary TWEAK levels were highest in the SLE without nephritis group, closely followed by the 
autoimmune /renal disease group. The SLE nephritis group had lower values, but was higher than the 
healthy Controls. However, the difference between these groups was not statistically significant. (p 
value = 0.888). Higher renal SLEDAI score had a higher median value of urinary TWEAK. However 
the values were not statistically significant (p value 0.174).Maximum levels of TWEAK levels were 
seen in Class III followed by Class II and then by IV lupus nephritis. The difference was not 
statistically significant (p = 0.174). There was mild positive correlation between TWEAK levels and 
anti ds DNA, and urine protein creatinine ratio. The difference was not statistically significant(p > 
0.05) .There was negative correlation between urinary TWEAK levels and serum creatinineand  
complement C3 and C4 levels but it was not statistically significant (p > 0.05).The ROC plot showed 
an Area under the curve of  0.46. The sensitivity of TWEAK for determining the disease activity was 
60.53% and the specificty was found to be 36.11%. The cut off value for determining the active disease 
was >  2.7 ng/ml. 
 
CONCLUSIONS 
Urinary TWEAK levels among paediatric age group could not differentiate lupus nephritis patients from SLE 
patients without renal involvement.  Urinary TWEAK levels were also elevated in children with other 
Autoimmune /renal diseases hence could not differentiate between SLE and non SLE patients. Urinary TWEAK 
had a positive correlation with renal SLEDAI score hence may be considered to show promise as a marker of 
activity in Lupus Nephritis. Urinary TWEAK showed positive correlation with ds DNA and urine protein 
creatinine ratio and negative correlation with creatinine and complement C3 levels. The TWEAK levels were 
not able to differentiate between the different Classes of Lupus Nephritis.Urinary TWEAK had a sensitivity of 
60.53% and specificty of 36.11% for diagnosing Lupus Nephritis among SLE patients. Hence it may be a better 
screening test rather than a diagnostic test. 
Keywords  
TWEAK, SLEDAI 
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INTRODUCTION 
 
Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disorder affecting 
mainly women of child bearing age, but around 20% of the cases are seen among 
children less than 18 years of age (1) . The disease is more active and is associated with 
rapid progression among children as compared to adult onset SLE (2,3). There is a 
higher incidence of renal involvement (lupus nephritis) in children worldwide ranging 
from 20-70% (2–6). Similar higher frequency of renal involvement has been 
documented in India as well (7–9).  
Renal involvement is one of the major factors determining the survival outcome among 
these children (3,10). The disease has a chronic course with remitting and relapsing 
period and hence warrants periodic monitoring. The overall prognosis has improved 
dramatically over the last decade, with the use of immune modulators and steroids but 
renal involvement continues to be the main cause of morbidity and mortality among 
these children. About 10-15% of the lupus nephritis patients still progress to end stage 
renal disease at 5 years of diagnosis (9,11,12). Early diagnosis and appropriate 
treatment of SLE among children is very important in order to prevent long term 
morbidity and mortality associated with the disease.  
Diagnosis of lupus nephritis is based on several markers like anti ds DNA antibodies, 
complement levels, urinary indices, etc. However the accuracy indices of these markers 
are far from satisfactory (13–15).  Renal biopsy is the gold standard but it is invasive 
and has limited application in repetitive testing for monitoring disease progression and 
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response to therapy. Hence the need for reliable markers which are easy to test, in a 
lesser invasive (blood) or non-invasive (urine) method which would help to diagnose, 
prognosticate as well as assess efficacy of therapy and monitor disease progression. 
Several candidate biomarkers are being evaluated with some of them appearing more 
promising(16–19). In our study we will be focusing on urinary TWEAK.TNF –like- 
WEAK – inducer of apoptosis (TWEAK) is  a new cytokine which was discovered in 
1997 (20). TWEAK is expressed by many inflammatory cells and mediates many pro 
inflammatory activities through its receptor Fn14 receptor which gets upregulated in 
injured tissues including kidney (21).  Increased expression of TWEAK and FN14 
receptor in both glomerular and tubular areas have been reported in patients with lupus 
nephritis suggesting that TWEAK/Fn14 pathway may contribute to the pathogenesis of 
lupus nephritis(22). Studies evaluating TWEAK as a marker of lupus nephritis are few 
but the findings are promising. In their cohort study, Schwartz et al 2006, 2009, found 
urinary TWEAK levels to be significantly higher in LN-SLE patients than in non-LN 
SLE patients and other disease- control groups (23,24).  Also, TWEAK was better in 
distinguishing LN-SLE and non LN-SLE patients, than other markers like anti ds DNA 
antibodies and complements.Perusal of literature which will be briefly summarized later 
clearly shows urinary TWEAK to be promising biomarker in lupus nephritis. Though 
some information on this aspect is available, very little is found on TWEAK in children 
and none from the Indian scenario. Hence this study was planned to assess the clinical 
utility of TWEAK in the care and the management of patients with lupus nephritis. We 
hope that urinary TWEAK level may increase the sensitivity and specificity of 
diagnosis, prognosis, assessing response to therapy and monitoring disease progression. 
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AIMS AND OBJECTIVES 
 
The objective of the study is to assess the utility of urinary TWEAK as a marker of 
lupus nephritis in children with Systemic lupus erythematosus. 
AIMS: 
1) To assess the accuracy of urinary TWEAK levels test as a marker of lupus 
nephritis amongst all children with newly diagnosed SLE 
2) To assess the correlation of renal SLEDAI score with urinary TWEAK level 
3) To assess the ability of urinary TWEAK levels to differentiate the class of lupus 
nephritis as per the histopathological findings (renal biopsy report)  
 
HYPOTHESIS: 
1) Urinary TWEAK level will differentiate between newly diagnosed SLE with or 
           without renal involvement. 
2) Urinary TWEAK levels correlate with histopathology- based class of lupus    
     nephritis. 
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LITERATURE REVIEW 
INTRODUCTION  
Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disorder, involving 
multiple organs, kidney being the most commonly affected organ. SLE with renal 
involvement (lupus nephritis) is diagnosed by urinary indices, anti ds DNA antibodies, 
complements and few other tests. But the accuracy indices are far from satisfactory. 
Kidney biopsy is the gold standard but it is an invasive procedure and has limited 
application in repetitive testing, for monitoring of renal involvement. Several newer 
biomarkers are considered promising.  Tumour necrosis factor (TNF) like weak inducer 
of apoptosis (TWEAK) is one such biomarker which has shown to be a promising 
biomarker for lupus nephritis. 
PATHOGENESIS OF SLE 
SLE is an autoimmune disorder which results from loss of self tolerance to nuclear 
antigens and defect in normal haemostatic mechanism of apoptosis.  
Normally during cellular degeneration nuclear components of the dead cells are 
opsonized by complements or removed by phagocytosis, thus preventing their exposure 
to extracellular compartments and to immune regulatory cells. 
In SLE patient, because of defective apoptosis, the nuclear antigens are exposed to 
antigen presenting cells which lead to the immunization against the nuclear antigen by 
the plasma cells and memory T cells. Also in SLE, there is compromise of elements 
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which distinguishes self nucleic acids from that of a virus. This leads to activation Toll-
like receptors which triggers an antiviral immunity response against self nucleic acids. 
 
Figure A: Pathogenesis of SLE outside kidney (Adapted from Lech et al, www.jasn.org) 
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CLASSIFICATION CRITERIA 
Due to varied clinical as well as laboratory manifestations of SLE, diagnosis of SLE is 
made based on classification criteria by the revised American College of Rheumatology 
(ACR) which are currently used by rheumatologists worldwide.    
The criteria for classification were published by Cohen et al in 1971. This criteria was 
subsequently revised by Tan et al(25) in 1982 to include new serological tests. The 
currently used ACR criteria was revised in 1997 further to include SLE antibodies  
(26). According to this classification, a patient is diagnosed to have SLE if 4 or more 
out of the 11 criteria are present either simultaneously or serially over time.  
However this classification is based on adult population and there were no separate 
classification criteria available for childhood SLE. But studies are available which 
validated the use of the current 1997 ACR classification criteria for paediatric SLE. One 
such study done by Ferraz et al(27)evaluated the validity of the 1997 ACR criteria had 
both 100% sensitivity as well as specificity in diagnosing children with SLE and hence 
showed that this ACR classification criteria is as accurate when applied to paediatric 
population as it is among adult SLE (46).  However another study done by Tucker et 
al(28) stated that the clinical profile of paediatric onset SLE are less characteristic as 
compared to adult disease and also often children present primarily with renal 
manifestation at onset but lack other criteria for diagnosis of SLE. 
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DRAWBACK OF THE 1997 ACR CLASSIFICATION 
CRITERIA 
The currently used 1997 ACR classification criteria have not been validated further 
inspite of the following drawbacks. 
1) The criteria has less sensitivity in detecting early disease which might not present with    
   the classical manifestations of SLE since it may take considerable amount of time for  
   the patient to manifest atleast 4 criteria 
2)  Low complement levels which are seen very commonly at the time of diagnosis or   
   during disease flare is not included in the current 1997 ACR classification criteria 
3) This criteria was developed based on studies among the Caucasians and does not take  
   into consideration of ethnicity despite many studies showing variations of clinical  
  manifestations among different ethnic groups. 
4) The current 1997 ACR classification criteria was not developed for diagnosing SLE 
  but was actually meant for clinical research purposes. 
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REVISED 1997 ACR CLASSIFICATION CRITERIA  
 
 
CRITERIA DESCRIPTION 
1. Malar rash Raised or flat, fixed erythema over malar prominences, sparing 
the nasolabial folds 
2. Discoid rash  Scaly raised patchy erythema with keratosis 
3. Oral ulcers Painless ulcers  
4. Photosensitivity Rash on sunlight exposure 
5. Arthritis  2 or more joints involved with tenderness or joint effusion 
6. Renal involvement Proteinuria of more than 0.5gm/day or urinary dipstick protein of more 
than 3+  OR 
Urinary casts  
7. Serositis Pericarditis or pleuritis 
8. Haematological 
involvement  
Haemolytic anemia OR 
Thrombocytopenia with platelet less than  100,000/cu mm OR 
Leukopenia with counts less than 4000/cu mm OR 
Lymphopenia with lymphocyte counts less than 1500/cu mm 
9.  Neurological 
involvement 
Psychosis or seizure 
10.  Antinuclear antibody ANA positive 
11.  Immunological 
involvement 
 Anti ds DNA positive OR 
Anti Smith antibody positive OR 
Anti phospholipid antibody positive 
16 | P a g e  
 
1. MALAR RASH   
Cutaneous manifestations of SLE can be divided into acute and chronic lesion. 
Malar rash is an acute lesion which is typically described as erythematous rash 
present over the malar prominences with sparing of the nasolabial folds and the 
lesion is exaggerated by ultraviolet light exposure. The rash is classically described 
as ‘butterfly’ rash. Studies have shown that malar rash is seen commonly in 
paediatric age group also (26,29) .  
Studies in India have also shown higher incidence of malar among children with 
SLE. Study done in our own institution by Agarwal et al, Vellore 2009 showed 
57.1%  of  SLE children having malar rash (8).  
Other Indian studies like Chandrasekaran et al, Madras1994 showed malar rash in 
59% of SLE patients (7)  but Singh et al, Chandigarh 2015 showed higher incidence 
of malar rash (87%) among SLE patients (30) 
 
 
 
Figure B Malar rash in paediatric SLE (Adapted from Color Atlas of Paediatric 
Dermatology) 
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2. DISCOID RASH 
This distinct erythematous scaly plaque is a chronic cutaneous lesion which can 
progress to keratotic lesions with scarring, mainly on face and scalp. This lesion 
can lead to alopecia if present on the scalp.  However this rash is less commonly 
seen among paediatric SLE group as compared to adult onset SLE (26,29) and is 
seen in less than 10% of paediatric SLE cases (31) 
 
 
Figure C discoid rash causing scarring alopecia (Adapted from DermNet NZ) 
 
3. ORAL ULCERS  
These ulcers are described as painless ulcers which are predominantly found 
on oral and nasopharyngeal cavity and because of their painless nature it can 
be easily missed during examination unless diagnosis of SLE is specifically 
considered. These ulcers are found more commonly among paediatric onset 
SLE as compared to adult onset SLE, more so among Asian paediatric 
population as compared to Western population (29,32,33). Huang et al 2010 
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showed that 20 -40 % of SLE children in Asia had oral ulcers at the time of 
presentation (32). Mondal et al 2010 showed 21% (34) and Singh et al 1997 
showed 25% (30)incidence of oral ulcers among Indian children with SLE. 
 
Figure D: Oral ulcer (www.medicalzone.net) 
  
4. PHOTOSENSITIVITY  
SLE patients have unusually strong reaction to ultraviolet sunlight exposure which 
can result in malar rash or even a disease flare. These phenomenon are more 
common in adult SLE population (47).  Photosensitivity was more often found in 
chronic disease of long duration (29) 
5. ARTHRITIS  
SLE arthritis are non erosive and mainly involve peripheral joints, 2 or more in 
numbers, and are characterized by presence of joint tenderness or effusion.  
Arthritis is seen commonly in paediatric onset SLE.. In Australia, incidence of 
arthritis among SLE patients was 76% (35). In other Asian countries, arthritis was 
less common among paediatric SLE patients. In Taiwan,Lee et al (36) showed only 
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37% of SLE children having arthritis and in Singapore, by Tan et al (25), arthritis 
was seen among 56.3% of SLE patients.  
       However studies in India have showned higher incidence of arthritis among SLE  
       patients. Study in our institution by Agarwal et al 2009 showed 65% of   SLE   
       patients having arthritis (8). Similar higher incidence were shown by other Indian 
       studies like Singh et al,1997 which showed 87% involvement  (30) and  
      Chandraserakan et al 1994 showing 86.6% of SLE  patients with  arthritis (7) 
6. RENAL INVOLVEMENT  
Renal involvement in SLE is described by presence of persistent proteinuria greater 
than 0.5gm per day or urinary dipstick of 3+ proteins and/or presence of urinary 
cellular casts including tubular, granular, red blood cells, haemoglobin or mixed. 
Renal involvement (lupus nephritis) is one of the most common manifestations of 
SLE seen among paediatric age group (6,30,32,38–42). Similar studies done in 
India have also showed higher incidence of renal involvement among paediatric 
onset SLE (7,8,37).  Renal disease develop within two years of onset of disease in 
about 90% of the paediatric SLE population (38). Most often found renal 
involvement  are  nephrotic  range proteinuria, haematuria, hypertension and renal 
failure (9,38,39).  
The most frequently found histopathological lesion in renal biopsy is class IV lupus 
nephritis (diffuse proliferative) (9,10,46,47). Renal involvement is one of the major 
factors determining the survival outcome among paediatric onset SLE  (3,10). 
Studies done in our institution by Agarwal et al 2009 showed 77.1%  renal 
involvement with histopathological Class II and IV as the most common lesion (8) 
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whereas other Indian studies like Chandraserakan et al 1994 reported 49.1% (7) and 
Singh et al 1997 reported 56.2% renal involvement (30).  
7. SEROSITIS  
Serositis involves inflammation of either the pleura or the pericardium. Patient   
can presentwith pleuritic chest pain or pleural effusion in pleuritis. They can  
also present with pericardial rub or pericardial effusion in pericarditis.  
Serositis manifestation are however, more common among adult onset SLE  
rather than paediatric SLE (34, 40,50).   
8. HAEMATOLOGICAL INVOLVEMENT  
Being an autoimmune disease, SLE disease is associated with haematological 
involvement which is characterized by presence of autoimmune haemolytic anemia 
(Coomb’s positive) associated with reticulocytosis. Anemia can also be due to 
chronic disease. Thrombocytopenia (platelet count less than 100,000 per cu mm) 
and leucopenia (total blood count less than 4000 per cu mm) are also commonly 
seen in SLE patients. They are considered to be due to autoantibodies which are 
directed against the cell surface antigens.  Haematological manifestations are more 
commonly seen among childhood SLE. (35,40,41). Study done in Singapore by Tan 
et al, 2015 showed that haematological abnormality (lymphopenia followed by 
haemolytic anaemia and thrombocytopenia) was the most common manifestation 
among children with SLE (25).  More than 50% of childhood SLE patients present 
with cytopenia, mild leukopenia being the most common finding (31) 
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9. NEUROLOGICAL INVOLVEMENT  
American College of Rheumatology, 1999 has defined 19 neuropsychiatric 
syndromes associated with SLE.  25 – 65 % of paediatric SLE children can develop 
neuropsychiatric symptoms during the course of disease (42,43).     One fourth of 
these children with neuropsychiatric symptoms can have permanent neurological 
damage (42) . Among the symptoms, headache and psychosis are the most 
commonly manifested neuropsychiatric symptoms (42,43). Mackie et al in 
Australia showed only 3% of children with SLE having neuropsychiatric features 
(35).  Similarly other Asian studies also showed lower incidence with only 4.5% 
neurological involvement in Singapore by Tan et al (25) and 10.5% in Taiwan by 
Lee et al (36) 
However in Indian studies neurological involvement was found to be more 
common as compared to other countries. Agarwal et al showed 21.4% 
neuropsychiatric manifestations among SLE patients (8). Comparatively Singh et al 
showed 23.6% (30) and Chadrasekaran et al showed 27.1% of SLE children with 
neuropsychiatric manifestions (7).  
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   ACR Neuropsychiatry syndromes seen in SLE (44) 
Central Nervous System Peripheral Nervous System 
Aseptic meningitis Guillain Barre syndrome 
Headache Mononeuropathy 
Cerebrovascular disease Polyneuropathy 
Seizures  Cranial neuropathy 
Movement disorders Plexopathy 
Demyelinating syndrome Autonomic disorder 
Myelopathy Myasthenia gravis 
Mood disorder  
Anxiety   
Psychosis  
Cognitive dysfunction  
Acute confusional state  
 
10. ANTINUCLEAR ANTIBODY 
     Positive antinuclear antibody demonstrated by ELISA or immunofluorescence 
assay at any time during the disease course is seen in majority of the SLE patients.  
ANA positivity had sensitivity rate of 95 to 98% among paediatric SLE patients 
(25,43). However it had a low specificity rate of around 36 % as demonstrated by 
Copple et al, 2011 (45) and also paediatric SLE cases with negative ANA has been 
reported. 
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     Enriquez et al in 1988 had reported three children with renal biopsy proven lupus 
nephritis but who were ANA negative (46).  
11. IMMUNOLOGICAL INVOLVEMENT  
SLE is an autoimmune disorder characterised by production of autoantibodies. So 
even though ANA positivity is considered as the hallmark of SLE, various other 
autoantibodies are present which collectively help in a more accurate diagnosis of 
SLE. So according to the 1997 revised ACR classification criteria, presence of anti 
ds DNA antibody or anti Smith antibody or antiphospholipid antibodies are 
predictive of immunological involvement in SLE. A meta analysis study done by 
Livingston et al, 2012  showed that  among these autoantibodies, anti ds DNA 
antibody was the most commonly found autoantibody in paediatric SLE group with 
odds ratio of 1.97: 95% confidence interval of 1.31 to 2.96 (47). However Tarr et 
al, 2015 found that anti-DNA antibody were detected equally among adult as well 
as paediatric onset SLE (82% in paediatric SLE versus 85% in adult SLE ) (48) 
Another meta analysis by BIZZARO et al (49) demonstrated  that neither anti-ds 
DNA antibodies was significantly associated with the SLE disease activity (p = 
0.256) nor was it correlating with renal involvement.  
In paediatric SLE, Hiraki et al (50) also found that after ANA, anti-DNA antibodies 
was the most common autoantibody (84% ) but did not find any significant 
correlation of anti-DNA antibodies with renal disease (P > .01) 
       Esdaile et al found anti ds DNA antibodies to have sensitivity of 50% and 
       specificity of less than 75%. Also it was found to be a poor predictor of disease  
       activity (13,14).  
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While looking at complements level C3 and C4 in SLE, Birmingham et al found C3 
with sensitivity of 27% and specificity of 70% as compared to C4 with sensitivity 
of 26% and specificity of 49%. During renal flare, only C3 level correlated with 
renal activity (p < 0.001) (51).  
In India, Agarwal et al found anti ds DNA antibodies to be positive in 77.1%  with 
low C3, C4 levels in 80% (8) while Chandrasekeran et al showed 92.3% ds DNA 
antibodies positivity with 50% low C3 among paediatric SLE cases (7) 
           
 
       Figure E : Distribution of SLE features (Adapted from Terao et al, Lupus 2014) 
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BIOMARKERS OF SLE 
BIOMARKERS  INDICATORS  
Anti ds DNA 
 
Disease flare 
Renal involvement 
C3 and C4  
 
Disease flare 
Renal involvement 
Anti C1q Disease activity 
Lupus nephritis 
Urinary TWEAK  Renal flare 
Urine MCP-1  Renal flare 
Anti C1q and anti ds DNA Renal flare 
Anti phospholipid and  
 anti ribosomal P protein 
Neuropsychiatric SLE 
 
ASSESSMENT OF DISEASE ACTIVITY  
Systemic lupus erythematosus is a disease with remitting and relapsing course. The 
disease flare is diagnosed by using both clinical and laboratory features. Different tools 
for assessment of disease activity are available. Some of the commonly used disease 
activity indices are the following: 
1) SLE disease activity index (SLEDAI) 
2) British Isles lupus assessment group (BILAG)  
3) Systemic lupus activity measure (SLAM) 
4) European consensus lupus activity measurement (ECLAM) 
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Of the indices described, SLEDAI and SLAM are found to be the most user-friendly 
(52). SLEDAI score gives more attention to renal disease when compared to SLAM (16 
points versus 8 points). Hence it is more helpful in assessing SLE patients with renal 
involvement (53).  Renal SLEDAI includes only 4 parameters which are used to assess 
renal disease activity – proteinuria, haematuria, pyuria and urinary casts. So far renal 
SLEDAI has been found to be best for measuring lupus nephritis activity among the 
currently available indices (54).  
SLEDAI score has been added in the Annexure I 
EPIDEMIOLOGY 
INCIDENCE AND PREVALENCE WORLDWIDE 
About 15-20% of systemic lupus erythematosus cases are seen among children less than 
18 years of age (1,32,33,55). Incidence of SLE among children differs according to the 
ethinicity with higher frequency of incidence in Asian, Hispanic, African American, 
Australian aboriginals and Native American as compared to Caucasians. Incidence 
varies widely across the countries of the world ranging from 0.36 to 2.5 per 100,000  in 
countries like America, United Kingdom and Australia to about 31/100,000 per year 
among Asian countries (3,35,43). Prevalence  of childhood onset SLE varies from 1.89 
to 25.7 per 100,000  (56) 
TRENDS IN SOUTH EAST ASIA 
Studies in South East Asian countries have shown a higher prevalence of childhood 
SLE as compared to Western countries. In Taiwan the prevalence rate was  6.3  per 
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100,000 (57)  while  another study in Singapore showed a prevalence of 14.2 per 
100,000 children (25).  A study done by Huang et al, 2010 showed prevalence of 
paediatric onset SLE as 6.3 to 19.3 per 100,000 children in Asia (32) 
INCIDENCE AND PREVALENCE IN INDIA 
There is paucity of reports in India regarding the incidence and prevalence of childhood 
onset SLE. Study done in Eastern India showed that 3.9% of all paediatric 
rheumatological cases were SLE patients (37). Another study done in North India 
showed a point prevalence of 3.2 per 100,000 (58) 
SEX DISTRIBUTION 
Like in adult, females are more commonly affected in SLE among children with male : 
female ratio ranging from 1: 2 to 1: 7 (7,8,32,37,43). Huang JL et al, 2004 found that 
the prevalence among girls was 6.2 times higher than those among boys (57). A study 
done in our own institution by Agarwal et al, 2009 showed male : female ratio of 1:6 
(8) 
AGE DISTRIBUTION 
Most of the childhood SLE have disease onset between 5 to 16 years of age (32,43,48). 
In Agarwal et al study, 2009 the mean age group of SLE was found to be 10.5 year 
(range 4 to 15 years) and in Singh et al (30) it was 10 years. Female patients are found 
to develop disease onset at a younger age than compared to male counterpart  (29) 
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DIFFERENCE BETWEEN ADULT AND PAEDIATRIC ONSET SLE 
The disease is more active and is associated with rapid progression among children as 
compared to adult-onset SLE (2,5,28,55,59). Clinical manifestations also differ between 
adult and childhood onset SLE.  Features like fever, mucocutaneous lesions, renal 
,neurological, haematological problems and polyarthritis were more common in 
children (5,33,59,60). Childhood SLE may have different autoantibody profiles 
(increased anti–dsDNA and anticardiolipin antibody, less rheumatoid factor), and more 
disease activity than adult-onset SLE 
RENAL INVOLVEMENT IN PAEDIATRIC SLE 
There is a higher incidence of renal involvement (lupus nephritis) in children worldwide 
ranging from 20 to 70% (6, 30, 32, 40–42). Similar higher frequency of renal 
involvement has been seen in India as well (7,8,37).  
Renal involvement is one of the major factors determining the survival outcome among 
these children (2,3,10,33,59). Renal involvement is most commonly manifested by 
nephrotic range proteinuria, haematuria, hypertension and high creatinine(9,12,61).  
In Lee et al study, proteinuria was seen in 51.3%, haematuria in 44.4% and cellular cast 
in 10.5% of the paediatric SLE cases (36). Tan et al in Singapore found haematuria 
more commonly (50%) followed by proteinuria (39.1%) (25).  
Singh et al study showed proteinuria in 94.4%, haematuria in 62.5%, hypertension in 
37.5% and high creatinine in 19.4% among paediatric SLE (30).  
 Most frequently seen histological finding in renal biopsy among lupus nephritis is class 
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IV nephritis (diffuse proliferative) (9,12,36,39).  
When renal parameters were compared with the class of lupus nephritis, it was found 
that proteinuria, haematuria, hypertension and elevated creatinine level correlated with 
higher classification of lupus nephritis. Studies in paediatric age group also showed 
similar findings with Class IV lupus nephritis group being found to have higher 
incidence of nephrotic range proteinuria (p <0.05) as compared to other classes in Yang 
et al study (62). Agarwal et al also showed Class IV lupus nephritis to be more 
commonly associated with high creatinine (83.3%), haematuria (66.6%), hypertension 
(61.5%) and proteinuria (58.1%) (8) 
LUPUS NEPHRITIS 
 
Renal involvement (Lupus nephritis) is one the most common clinical manifestations of 
paediatric SLE. Incidence of lupus nephritis among paediatric SLE ranges from 20 to 
70% (6, 30, 32, 40–42).  Similar higher frequency has been documented in India as well 
(36 - 39). Lupus nephritis is more active in childhood SLE and is one of the major 
factor determining the survival outcome among these children with around 10-20% of 
these children developing end stage renal disease eventually (2,3,10,33,59). 
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PATHOGENESIS OF LUPUS NEPHRITIS 
 
Figure F :Pathogenesis of Lupus nephritis (Adapted from Marc C, Rheumatology) 
PROPOSED MECHANISM OF TISSUE INJURY IN LUPUS NEPHRITIS 
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Figure G : Proposed mechanism of immune complex deposition in Lupus nephritis 
(Adapted from J Clin Cell Immuno, 2014) 
DEPOSITION OF IMMUNE COMPLEXES  
Deposition of autoantibodies as immune complexes is a pre requisite for development 
of lupus nephritis (63).  Anti ds DNA antibodies are the most commonly linked 
autoantibody in development of lupus nephritis (64).  The exact mechanism of immune 
complexes deposition in the glomerulus is not known but there are few postulations.  
Three theories have been postulated so far: 
1)  Deposition of circulating preformed serum immune complexes 
2)  In situ binding of the autoantibodies to endogenous glomerular antigens 
 3) Direct binding of autoantibodies to endogenous glomerular antigens like apoptotic 
     DNA/ nucleosomes (‘planted antigen’)  (63,65–67).  
ROLE OF COMPLEMENT IN LUPUS NEPHRITIS  
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Figure H : Classical complement activation pathway in Lupus nephritis 
(Adapted from Arch ImmunolTherExp, 2013) 
Complement activation has a significant role in the pathogenesis of lupus nephritis. 
Both classical and alternative pathways are activated in lupus nephritis (66,68,69).  
Initially classical complement pathway is activated by C1 which binds to the Fc part of 
the immune complexes and results in release of C3 convertase .Simultaneously the 
alternative pathway is also constantly activated which results in further generation of 
C3 convertase. C3 convertase cleaves C3 into C3a and C3b opsonin which results in 
amplification of the activation signals. C3b also generates C5 convertase, which finally 
leads to lysis of the target cells (66,68–70).  
 
ROLE OF CYTOKINES IN LUPUS NEPHRITIS  
 
Figure I : Cytokines role in pathogenesis of lupus nephritis (Adapted from Iwata 
et al, journal of Biomed and biotech, 2011) 
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CYTOKINES 
 
MAJOR EFFECTS 
TNF Tissue damage 
IFN gamma Tissue damage and inflammation 
IL-1  Tissue damage 
IL-4 Tissue fibrosis 
IL-6 Increased cellularity 
IL-8  Leucocyte infiltration 
IL-10  Apoptosis induction 
IL-18  IFN gamma stimulation 
TGFβ Tissue fibrosis 
 
Immune complexes deposition leads to activation of complement cascade which further 
causes activation and proliferation of mesangial cells. These activated mesangial cells 
are responsible for production of various cytokines and chemokines which leads to 
amplification of the inflammatory processes in the glomerular disease (71). In addition, 
studies on human cultured mesangial cells have shown anti ds DNA antibodies to 
induce release of cytokines like interleukin 1β, interleukin 6 and tumour necrosis factor 
(TNF α ) (72). Hence it can now be established that both immune complexes and 
autoantibodies are responsible for release of cytokines which further amplifies the 
inflammatory processes seen in lupus nephritis.  
CYTOKINES IN LUPUS NEPHRITIS 
The main cytokines present in lupus nephritis are the T-helper type 1 cytokines. They 
produce interleukin -12, interleukin – 18 and interferon gamma. (73) 
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Overexpression of inerleukin -12 and interleukin – 18 has been observed in glomeruli 
of mouse as well as human lupus nephritis which resulted in leucocyte infiltration and 
nephritic renal pathology with proteinuria (74). Interleukin -18 and interleukin -12 
inturn causes upregulation of interferon gamma which is responsible for the apoptotic 
destruction renal cells seen in lupus nephritis (75) 
Another cytokine which was discovered recently in 1997 and proven to be associated 
with the pathogenesis of lupus nephritis belongs to the tumour necrosis superfamily 
(20). The cytokine TWEAK (tumour necrosis factor weak inducer of apoptosis)  
stimulates mesangial cells to secrete proinflammatorychemokines like MCP -1, 
RANTES (CCL5),  CXCL-1, CVCAM-1 which leads to recruitment of activated T cells 
resulting in the pathogenesis of lupus nephritis (76–78) 
CHEMOKINES IN LUPUS NEPHRITIS 
Chemokines help in recruitment of inflammatory cells in the kidney. Some of the 
chemokines are monocyte chemo attractant protein (MCP-1), RANTES (CCL5), CCL4, 
CXCL10 and macrophage colony stimulating factor. Out of these chemokines, 
monocyte chemo attractant protein (MCP -1) has been demonstrated to be associated 
with renal damage in lupus nephritis (73,79). 
INFLAMMATORY CELLS  
Both B cells and T cells contribute in the pathogenesis of lupus nephritis.  
T CELLS IN LUPUS NEPHRITIS  
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T cells contribute to kidney injury by various mechanisms like cytokine production, 
recruitment of other inflammatory cells like macrophages and dendritic cells and 
activation of antibody producing B cells. In fact studies have shown that blockage of T 
cell activation as well as T cell depletion  have reduce the progression of renal damage 
in mouse models with lupus nephritis (69,80,81).  
B CELLS IN LUPUS NEPHRITIS  
 
B cells are primarily responsible for production of plasma cells which inturn produces 
auto antibodies which are responsible for immune complexes deposition followed by 
cascade of inflammatory processes seen in lupus nephritis (69,82).  
Overall, release of cytokines and chemokines results in influx of inflammatory cells like 
T cells, B cells and macrophages, ultimately causing renal injury and fibrosis (69). 
 
PATHOLOGY OF LUPUS NEPHRITIS  
Glomerular lesions in lupus nephritis have a diverse histo- pathological manifestations 
and hence the need for a classification system which will help not only in primary 
patient care but also assist in clinical trials and response to therapy in terms of 
improvement of renal lesion.  
First such classification was made by WHO in 1974 which subsequently underwent 
modifications in 1982 and 1995. The currently used revised classification was proposed 
by Renal Pathology Society and International Society of Nephrology in 2003.  
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Histological examination of minimum of 10 glomeruli is required to exclude any focal 
lesion. Immunofluorescence study should be done for IgA, IgM, and IgG along with C3 
and C1q complement components.  
 
1974 WHO CLASSIFICATION OF LUPUS NEPHRITIS  
 
CLASS I  
 
Normal glomeruli by light microscopy, immunofluorescence, electron 
microscopy 
 
CLASS II 
 
Purely mesangial disease 
IIa : normocellularmesangium by light microscopy but mesangial 
deposits by immunofluorescence and electron microscopy 
IIb : mesangial hypercellularity with mesangial deposits by 
immunofluorescence or electron microscopy 
CLASS III Focal proliferative glomerulonephritis (< 50%) 
 
CLASS IV  Diffuse proliferative glomerulonephritis (>/= 50%) 
 
CLASS V  Membranous glomerulonephritis  
 
CLASSIFICATION OF LUPUS NEPHRITIS (based on International Society of 
Nephrology/ Renal Pathology Society, 2003) 
CLASS I LUPUS NEPHRITIS  
It is defined as minimalmesangial disease with mesangial immune deposits 
demonstrated by immunofluorescence  
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Figure J: Class I lupus nephritis (Adapted from Scientific world journal, 2014) 
CLASS II LUPUS NEPHRITIS 
Also known as mesangioproliferative lupus nephritis, it is characterized by mesangial 
hyper cellularity associated with immune deposits in mesangium.  Sub epithelial or sub 
endothelial deposits may be demonstrated by electron microscopy or 
immunofluorescence . 
 
Figure K: Class II Lupus Nephritis (Adapted from Scientific world 
journal, 2014) 
CLASS III LUPUS NEPHRITIS 
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It is defined as focal lupus nephritis which involves less than 50% of the glomeruli. It 
was involves description of active or chronic lesions based on the presence of focal 
proliferation or focal sclerosis respectively. 
 
Figure L: Class III Lupus nephritis (Adapted from Scientific world journal, 2014) 
CLASS IV LUPUS NEPHRITIS 
It is defined as diffuse proliferative lupus nephritis which involves more than 50% of 
the glomeruli. It is subdivided into segmental and global proliferation. It can also be 
further subdivided into diffuse segmental (ClassIV-S) when more than 50% of 
glomeruli show segmental lesions and diffuse global (Class IV – G) when more than 
50% of glomeruli shows diffuse proliferation. The description should include 
proportion of glomeruli which are affected by active or chronic lesions. 
 
Figure M : Class IV Lupus nephritis (Adapted from Scientific world journal, 
2014) 
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CLASS V LUPUS NEPHRITIS 
It is defined as membranous lupus nephritis with segmental or global subepithelial 
deposits with or without mesangial hypercellularity.  
 
Figure N : Class V Lupus nephritis (Adapted from Scientific world journal, 2014) 
CLASS VI LUPUS NEPHRITIS 
It is defined as advanced sclerotic lupus nephritis with more than 90% of the glomeruli 
undergone glomerulosclerotic changes and without any evidence of active disease. 
 
Figure O : Class VI Lupus nephritis (Adapted from Hepinstall's pathology of 
kidneys) 
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ABBREVIATED ISN/RPS Classification of Lupus nephritis 
 
CLASS I  
 
Minimal mesangial lupus nephritis 
CLASS II  Mesangioproliferative lupus nephritis  
 
CLASS III  
 
Focal lupus nephritis  
CLASS IV  
 
Diffuse segmental or Global lupus nephritis 
CLASS V  
 
Membranous lupus nephritis 
 
The most common histological lesion found in paediatric SLE is Class IV  
(diffuse proliferative) followed by Class III (focal lesion) and Class II 
(mesangioproliferative) (10,38,39,62).  Indian studies also showed similar 
predominance of class IV lupus nephritis. Singh et al 2015 study had Class IV in 66% 
followed by Class II in 18.9% of patients (83) . Hari et al 2009 also showed higher 
incidence of Class IV (48.1%) followed by Class II (18.5%) (9). However Agarwal et al 
2009 showed equal distribution of  Class IV and Class II in 44.4%  followed by Class 
III in 4.3% of paediatric lupus nephritis cases (8).  
RENAL BIOPSY IN LUPUS NEPHRITIS  
Renal biopsy is the gold standard for diagnosis of lupus nephritis. Similar clinical 
features may be seen in patients with different classes of lupus nephritis. This is 
particularly important since aggressive treatment with harmful side effects are generally 
reserve for more progressive renal disease. Therefore renal biopsy should be done 
earlier during the disease course in order to plan early treatment (84). Studies have 
shown that renal damage in lupus nephritis over the last decade have decreased due to 
early diagnosis and timely treatment (85)Faurschou et al, 2006(86) study showed that 
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delay in renal biopsy following the onset of nephritis constituted one of the risk factors 
for end stage renal disease (86) .However lupus nephritis has a chronic course with 
remitting-relapsing period and hence warrants periodic monitoring. Repeat renal biopsy 
especially in children has limited application. Also there are no clear consensuses 
available for repeat renal biopsy in lupus nephritis. The most common reason for repeat 
renal biopsy is when the patient has worsening renal functions like persistent 
proteinuria, raising creatinine or worsening urinary sediments. The other most common 
reason is when the patient does not respond during induction therapy (87) 
 
BIOMARKERS IN LUPUS NEPHRITIS  
DIAGNOSIS Anti ds DNA antibodies 
 C4d – erythrocyte/platelet bound 
ACTIVITY  Anti ds DNA antibodies 
 Complements : C3,C3a,c3d, C4, C5a, C4d 
 Cytokines : IL-6, IL-12, IL-10,IL-15,IL-18, IFN 
gamma, TNF α 
 Endothelial activation markers : sICAM, sVCAM 
 Acute phase proteins : CRP, ferritin 
 
RENAL INVOLVEMENT 
Anti ds DNA antibodies 
Anti C1q  
Urinary VCAM and MCP-1  
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Urinary NGAL 
Urinary TWEAK (tumor necrosis factor–like weak 
inducer of apoptosis) 
 
As mentioned earlier, repeat renal biopsy for monitoring lupus nephritis disease 
progression and response to therapy is not applicable especially in paediatric group of 
patients. Also many studies have shown that the currently available markers for 
diagnosis of lupus nephritis like anti ds DNA, complement levels and urinary indices 
have varying accuracy levels and their levels do not correlate well with the disease 
activity(13–15).   
Several biomarkers are being evaluated with some of them showing promising results. 
A summary of the markers evaluated can be found in the reviews of Shwartz et al 2007 
(88), Manmohan &Madaio 2010 (89), Herst et al 2012 (90), Bennet& Brunner 2013 
(91).  
In the present study our focus in on urinary TWEAK (TNF like WEAK inducer of 
apoptosis) 
TWEAK (TNF like WEAK inducer of apoptosis)  
TWEAK (TNF like WEAK inducer of apoptosis) is a new cytokine which was 
discovered in 1997  and belongs to TNF superfamily (20). TWEAK is expressed as a 
soluble cytokine by various inflammatory cells like leukocytes, macrophages, dendritic 
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cells and natural killer cells. It has been found to be involved in proinflammatory 
responses, vascular changes, cellular proliferation, apoptosis and fibrosis (21).  
TWEAK/Fn14 receptor expression in kidney  
Fn14 is the receptor for TWEAK is expressed on various cell types like epithelial, 
mesenchymal and endothelial cells.  In kidneys, it is expressed on mesangial cells, 
podocytes and tubular cells and also by the infiltrating leucocytes(76).  Normally Fn14 
is expressed at low levels but is readily up regulated in disease tissues and responsible 
for the inflammation and injury. Fn14 expression are increased by the proinflammatory 
cytokines like TNF α. IFN gamma and also by growth factors (76,92). 
  
TWEAK ACTIONS OF KIDNEY CELLS 
 
 
 
Figure P : TWEAK actions on renal cells (Adapted from Kidney 
International, 2011)  
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TWEAK ACTION ON RENAL CELLS  
Cell type Action 
 
Tubular cells  Proliferation 
Inflammation 
 
Mesangial cells  Proliferation 
Inflammation 
Apoptosis 
 
Podocytes Proliferation 
Inflammation 
 
 PROINFLAMMATORY EFFECTS  
The proinflammatory action of TWEAK includes release of various cytokines and 
chemokines which promote inflammatory cells infiltration followed by renal tissue 
damage. In fact studies have shown that TWEAK/Fn14 pathway deficiency or blockade 
is associated with decreased disease activity in renal disease models (87–89).  
VASCULATURE EFFECTS 
TWEAK has been shown to induce angiogenesis by activation of endothelial cells (93).  
However it is yet to be proven whether TWEAK has a role on the vascular permeability 
of the glomerular capillaries resulting proteinuria.  
EFFECTS ON MESANGIAL CELL PROLIFERATION 
Studies have shown TWEAK stimulating mesangial cell proliferation both in vivo and 
in vitro (94). Mesangial hyperplasia is one of the pathognomic features of lupus 
nephritis.  
 
EFFECTS ON APOPTOSIS 
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Renal injury and atrophy are seen in progressive lupus nephritis. TWEAK along with 
IFN gamma has been shown to induce apoptosis of mesangial cells (95). This statement 
has also been complemented by the study that TWEAK/Fn14 pathway  deficiency or 
blockade results in decreased renal inflammation (96).  
Recent studies on TWEAK have shown it to be a reliable marker for lupus nephritis in 
adult SLE patients. Studies have also show that TWEAK levels correlate with disease 
flare. The first study on TWEAK was done by Schwartz et al, 2009 (24) This 
multicentre cohort study was done on lupus nephritis with active disease and SLE 
without renal involvement. They also included four groups as control – healthy 
controls, other renal diseases due to hypertension or diabetes, rheumatoid arthritis and 
osteoarthritis patients. This study was primarily done among adult population with age 
ranging from 28 to 67 years of age. Urinary TWEAK levels were found to be elevated 
among lupus nephritis patients as compared to SLE patients without nephritis with 
median urinary TWEAK level of 12.54 (5.00 to19.38) pg/mgCr in active lupus nephritis 
versus 5.02(1.94 to 9.11) pg/mgCr (P < 0.001) in SLE patients without lupus nephritis.  
Urinary TWEAK levels were found to be significantly lower in the control groups – 
SLE without nephritis ( p = 0.005), rheumatoid arthritis group ( p = 0.013) and healthy 
control (p = 0.003) when compared to lupus nephritis  group.  
 TWEAK levels were shown to be a better predictor of renal involvement than anti ds 
DNA or complement levels with odds ratio of 7.36 (95% CI = 2.25 to 24.07, p value = 
0.001). They further showed that urinary TWEAK level peaked during lupus nephritis 
disease flare (p value < 0.05) (24).  
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Another study done by Xuejing et al, 2012 compared level of TWEAK among two 
groups – active lupus nephritis versus non active lupus nephritis with age group ranging 
from 14 to 53 years. Urinary TWEAK levels among active lupus nephritis were found 
to be elevated as compared to non – active lupus nephritis patients (10.29 ± 1.81 
pg/mgCr versus 2.14 ±0.30 pg/mgCr, P <0.01). They also found significant correlation 
between elevated urinary TWEAK and disease activity index (correlation coefficient 
0.825, p value <0.01). However the urinary TWEAK was not able to differentiate 
between different classes of lupus nephritis. Moreover the TWEAK levels among 
healthy controls were higher than those among SLE without nephritis cases. They found 
urinary TWEAK to have a low sensitivity of 50% and specificity of 90%  (97).  
Xuejing et al study (97) also did not look into the correlation between levels of urinary 
TWEAK and different histopathological class of lupus nephritis. 
TWEAK is considered to be of renal origin but there were studies which showed lower 
levels of TWEAK among renal diseases. Kralisch et al (98) and Carrero et al (99) found 
that serum TWEAK levels were low among renal disease patients on haemodialysis as 
compared to control patients (p <0.05).  
Though TWEAK is detected in both serum and urine, only urinary TWEAK has been 
found to correlate well with renal pathology in some studies done on adults. There are 
no reports on TWEAK either on children or among Indians. 
Hence this study has been done to assess the utility of urinary TWEAK in identifying 
renal involvement in children with SLE as well as to see if the TWEAK levels 
correspond with the disease flare or progression.  
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METHODOLOGY 
SAMPLE AND SETTING  
 
This study was conducted between October 2014 and September 2015 at Paediatrics 
unit II, CMCH, Vellore. Children presenting with SLE with or without lupus nephritis 
fulfilling the inclusion criteria were recruited. This included children who attended the 
Paediatric Rheumatology, Paediatric Nephrology OPD and those admitted in paediatric 
wards. Healthy children from general OPD who came for general check-up were also 
recruited as Controls. Recruited children were divided into four groups: 
1) Children with lupus nephritis 
2) Children with SLE but without lupus nephritis 
3) Children with other autoimmune disease and other renal disease 
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4) Healthy children 
The study and research procedures were fully explained to the parents and the 
patient and those who gave written consent and assent were allowed to participate in 
the study. The consent was obtained in the regional language that the parent/ patient 
was conversant (ANNEXURE II) 
 
 
 
STUDY DESIGN 
This is an observational study which was done to assess the utility of urinary TWEAK 
as a marker of lupus nephritis and correlate its level with the disease activity as 
indicated by the renal SLEDAI score. Urinary TWEAK level was also correlated with 
other pre-existing indicators of lupus nephritis like anti dsDNA and complements C3, 
C4 levels.  
PARTICIPANTS 
INCLUSION CRITERIA 
Group I: Children with SLE who were further subdivided based on biopsy report 
and renal SLEDAI score, into : 
Group Ia: SLE with lupus nephritis 
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Group Ib: SLE without lupus nephritis 
Group II : Disease controls which  included children with other autoimmune and 
renal diseases. 
Group III : Healthy controls which included healthy children with normal baseline 
investigation 
 
 
 
EXCLUSION CRITERIA 
Children whose parents/ legal guardian did not give consent were not included in this 
study. 
All the children meeting the inclusion criteria were enrolled into the study thus 
minimizing the chances of any selection bias. The urinary TWEAK test was done by 
the laboratory technicians in the nephrology department who was unaware of the patient 
groups thus minimizing the chances of bias. 
SAMPLE SIZE CALCULATIONS 
With an assumed sensitivity / specificity of predicting lupus nephritis using urinary 
TWEAK as 70% and a precision of 10% and a desired confidence interval at 95% we 
arrived at a sample size of 81 children in each group (SLE/ SLE with lupus nephritis/ 
disease control/healthy controls.  
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Sensitivity of the new test (%) = 70(expected sensitivity /specificity of urinary TWEAK 
in predicting lupus nephritis  
Precision (%) = 10 
Desired confidence level (%) = 95 
No. of diseased subjects needed = 81 
 
 
 
FUNDING AND APPROVAL 
Institutional Research Board approval  
The research proposal was discussed by the Institutional Review Board in July 2014 
and approval was obtained [IRB Min. No.9084 dated 06.10.2014]. 
There were no ethical issues related to this study. Institutional review board approval 
was obtained prior to the commencement of the study. The funds were used for the 
procurement of the TWEAK ELISA kits and for processing the samples  
DATA COLLECTION  
All children who fulfilled the inclusion criteria were enrolled into the study after 
explaining the study and obtaining the consent and assent forms. The data collection 
was done by the principal investigator in the case report form (Annexure III)  
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The following details were recorded specifically: 
1) Demographics – age, sex, body mass index 
2) Duration of disease 
3) Disease activity scores – SLEDAI , renal SLEDAI 
4) Laboratory parameters including haematological and biochemical tests. 
Assessment of disease activity using SLEDAI (SLE Disease Activity Score) was 
done for children in SLE group. Similarly, in children with Lupus nephritis 
Renal SLEDAI score was used to assess renal disease activity.  
Urine samples from all the children were collected and stored in the refrigerator. 
Urinary TWEAK levels were measured by using commercial ELISA kits. 
Urinary TWEAK levels were correlated with other markers of disease activity 
(anti dsDNA, C3 and C4, and renal SLEDAI score). TWEAK levels were also 
correlated with levels of proteinuria and class of lupus nephritis. TWEAK levels 
in normal healthy children were done to know the baseline normal values and 
served as controls. 
 
HUMAN TWEAK ELISA KIT 
This TWEAK ELISA is a quantitative competitive immunoassay which is 
manufactured by Neoscientific Company. Details of the assay procedure has been 
given in 
 Annexure IV. 
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DATA ANALYSIS AND STATISTICAL METHODS 
  
Data entry was done by the principal investigator in epidata software. (Annexure V) 
The results were analysed using STATA version 13.1 software. The statistical tests 
used were student t test, chi square test or Mann Withney U test, Fisher’s exact test 
based on the normality of distribution of the variables. 
Sensitivity and specificity values were calculated by using a 2x2 analysis for the 
diagnostic test. The validity and predictive value statistics were presented with 95 per 
cent confidence interval. The best cut off level of urinary TWEAK was identified using 
ROC analysis. 
 
STROBE FIGURE 
 
 
 
 
 
 
 
 
 
 
 
CHILDREN PRESENTING TO TERTIARY CARE 
CENTRE (WARD/OUTPATIENT CLINIC) 
 
STUDY INCLUSION CRITERIA* 
(N = 156) 
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RESULTS 
 
The prospective study was conducted over a period of 11 months (October 2014 – 
September 2015) in the Department of Child Health, Christian Medical College, 
Vellore, a tertiary care centre in South India. Children presenting to the outpatient 
department and inpatient wards who fulfilled the inclusion criteria and had none of the 
exclusion criteria were enrolled into the study. 
 Clinical history and detailed physical examination was done at the time of recruitment. 
The clinical data, as well as the serological and laboratory parameters (haematological 
and biochemical) were noted in a standardised proforma. 
GROUP Ia 
PATIENTS 
WITH SLE 
WITH LUPUS 
NEPHRITIS 
 
GROUP Ib 
PATIENTS 
WITH SLE 
WITHOUT 
NEPHRITIS 
 
GROUP II  
OTHER 
AUTOIMMUNE 
/RENAL 
DISEASES 
 
GROUP III 
HEALTHY 
CHILDREN 
 
URINARY TWEAK LEVELS 
n = Ia – 38/ Ib – 36/II – 21/ III - 40 
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A total of 156 children fulfilled the inclusion criteria (40 in lupus nephritis, 36 in SLE, 
40 in disease control and 40 in the healthy children group). These were included as the 
Study group. 
All participants and their legal guardians provided written consent to participate in the 
study prior to recruitment. 
The results were analysed in three parts :  
Part I – Demographic profile 
Part II – Comparison between lupus nephritis (Group Ia) and SLE without nephritis    
(Group Ib)    
Part III – Urinary TWEAK levels comparison between lupus nephritis (Group Ia), SLE 
without nephritis (Group Ib) and healthy control (Group III) 
PART – I: DEMOGRAPHIC PROFILE 
 
1) Age distribution 
 
   Table 1 : AGE DISTRIBUTION  
AGE NUMBER (n = 156) PERCENTAGE 
More than 10 years 102/156 65% 
Less than10 years  54/156 35% 
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Figure 1: AGE DISTRIBUTION 
 
Of the children recruited, 65% (102 /156)   were > 10 years of age while 35% (54/156) 
were < 10 years of age 
Table 2 : AGE DISTRIBUTION – MEDIAN AGE IN DIFFERENT GROUPS 
 
GROUP MEDIAN 
(years) 
RANGE 
(Minimum –Maximum) 
Lupus nephritis 
(n = 40) 
14 12 – 15.5 
SLE without nephritis 
 (n = 36) 
14 12 - 16 
Other autoimmune/ renal 
disease 
(n = 40) 
12.5 6.5 - 15 
Healthy controls 
(n = 40) 
8 6.5 - 11 
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Figure 2: MEDIAN AGE DISTRIBUTION 
 
The median age for group Ia and group Ib was 14 whereas it was 12.5 in the disease 
control group (other autoimmune and renal disease) and 8 in healthy controls. 
2)  Sex distribution 
 
Table 3 : SEX DISTRIBUTION  
SEX NUMBER OF PATIENTS 
 (n= 156) 
PERCENTAGE  
MALE 74/156 47% 
FEMALE 82/156 53% 
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Figure 3 : SEX DISTRIBUTION 
 
 In the study group, 53% (82/156)  were females whereas 47% (74/156) were males. 
 
 
 
Table 4 : SEX DISTRIBUTION - Group specific 
 
GROUP MALE 
(Percentage) 
FEMALE 
(Percentage) 
TOTAL (n) p  value 
Lupus nephritis 9 (22.5%) 31(77.5%) 40 <0.001 
SLE without nephritis  10 (27.8%) 26 (72.2%) 36 
Autoimmune/ renal 
disease 
28 (70%) 12 (30%) 40 
Healthy controls 27 (67.5%) 13 (32.5%) 40 
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Figure 4: SEX RATIO 
 Both Group Ia and Ib subgroups had significant female preponderance with M:F ratio 
of 1 : 3.4 in Group Ia and 1 : 2.6 ratio in Group Ib (p < 0.05) 
 
3) Body mass index 
 
Table 5 : MEDIAN BODY MASS INDEX IN DIFFERENT GROUPS 
GROUP MEDIAN  RANGE (Min –Max) p value 
Lupus nephritis 
(n = 40) 
19 16.2 – 21.6 < 0.001 
SLE without nephritis  
 (n = 36) 
18.4 15.9 – 21.2 
Other autoimmune/ renal disease 
(n = 40) 
15.5 14.1 – 17.6 
Healthy controls 
(n = 40) 
14.2 12.9 – 16.8 
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Figure 5: BODY MASS INDEX 
 
The group Ia and Ib subgroups had body mass index of 19 and 18.4 respectively.  
The disease control and healthy control had significantly lower body mass index of 15.5 
and 14.2 respectively ( p= <0.001) 
PART II: COMPARISON BETWEEN LUPUS NEPHRITIS AND 
SLE WITHOUT NEPHRITIS 
There were seventy six children with SLE. Of these, forty children had renal 
involvement (Lupus nephritis) and thirty six did not have any renal involvement (SLE 
without nephritis). These two groups were further compared for demography, clinical 
presentations and laboratory parameters.  
4) Disease duration 
 
      Table 6: MEDIAN DISEASE DURATION IN MONTHS 
GROUP MEDIAN  
( Duration in months) 
RANGE 
(Min –Max) 
P value 
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Lupus nephritis 
(n = 40) 
24 7.5 - 36 <0.254 
SLE without nephritis  
(n = 36) 
17 6 – 27 
 
24
17
0
5
10
15
20
25
30
LUPUS NEPHRITIS SLE
M
ED
IA
N
DISEASE DURATION (MONTHS)
DISEASE DURATION
(MONTHS)
 
Figure 6 : DISEASE DURATION (Months) 
Median duration of disease in group Ia patients was higher than that in group Ib patients 
(24 onths versus 17 months). The difference was not statistically significant. 
5) Clinical features 
 
Table 7 : CLINICAL FEATURES  
 (1997 ACR CLASSIFICATION CRITERIA) 
 
FEATURE LUPUS NEPHRITIS  
(n = 40) 
Number (%) 
SLE without nephritis   
(n = 36) 
Number (%) 
 
p value  
ANA positive 34 (85%) 36 (100%) 0.026 
Immune disorder 35 (87.5%) 32 (88.9%) 0.852 
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Arthritis 28 (70%) 23(63.9%) 0.571 
Haematological 23 (57.5%) 18 (50%) 0.512 
Malar rash 16 (40%) 19 (52.8%) 0.264 
Oral ulcer 16 (40%) 13 (36.1%) 0.727 
Photosensitivity 5 (12.5%) 11 (30.6%) 0.054 
Neurological  1 (2.5%) 6 (16.7%) 0.033 
Serositis 4 (10%) 2 (5.6%) 0.473 
Discoid rash 1 (2.5%) 0 >0.99 
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Figure 7 : CLINICAL FEATURES (1997 ACR Classification) 
ANA positivity and neurological involvement was significantly more in the SLE group 
compared to the Lupus Nephritis group (p<0.05). Rest of the clinical features were 
similar between the two groups. 
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6) Renal parameters in lupus nephritis  
 
      Table 8 : RENAL PARAMETERS IN LUPUS NEPHRITIS 
PARAMETERS LUPUS NEPHRITIS (n = 40) 
              NUMBER 
PERCENTAGE (%) 
PROTEINURIA 
Nephrotic range 
29/40 
13/29 
72.5% 
44.8% 
HAEMATURIA 24/40 60% 
PYURIA 24/40 60% 
URINARY CAST 6/40 15% 
72.5%
(29)
60%
(24)
60%
(24)
15%
(6)
RENAL PARAMETERS  (n = 40)
PROTEINURIA
HAEMATURIA
PYURIA
URINARY CAST
 
Figure 8: RENAL PARAMETERS IN LUPUS NEPHRITIS 
 
Among those with Lupus nephritis (Group Ia), proteinuria was present in 72.5% 
(29/40) 60% (24/40) each had haematuria and pyuria. Only 6 patients 15% (6/40) 
had urinary casts. 
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7) Renal SLEDAI score 
 
Table 9 : RENAL SLEDAI SCORE DISTRIBUTION 
Renal SLEDAI score NUMBER (n= 39) PERCENTAGE (%) 
ZERO 6 15% 
FOUR 8 20% 
EIGHT 7 17.5% 
TWELVE 13 32.5% 
SIXTEEN 5 12.5% 
 
 
Figure 9 - RENAL SLEDAI SCORE 
 
13/39 patients (32.5%) had renal SLEDAI score of twelve followed by 8/39 patients 
(20%) with renal SLEDAI score of four.  
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8) Classification of lupus nephritis 
   
Table 10 : LUPUS NEPHRITIS CLASSSIFICATION AT RENAL BIOPSY 
CLASS OF LUPUS 
NEPHRITIS 
NUMBER OF 
PATIENTS (n = 36) 
PERCENTAGE (%) 
Class II (Mesangial) 3 7.5 
Class III (Focal) 5 12.5 
Class IV (Diffuse) 26 65 
Class V (Membranous) 1 2.5 
Class VI ( Sclerosis) 1 2.5 
 
 
 
Figure 10: CLASSIFICATION OF LUPUS NEPHRITIS 
 
The predominant renal lesion was Diffuse Proliferative GN  (Class IV LN) in  65% 
(26/36) followed by Focal proliferative GN ( Class  III LN) in 12.5% (5/36)  
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Renal biopsy was not done for 4 patients. 
9) Laboratory parameters with histopathological  
classification 
 
Table 11: CORRELATION OF LABORATORY PARAMETERS WITH 
HISTOPATHOLOGY CLASS 
 
PARAMETER 
CLASS II  
 (n=3) 
CLASS III 
(n = 5) 
CLASS IV 
(n = 26) 
CLASS V 
(n = 1) 
CLASS VI 
(n = 1) 
p-value 
PROTEINURIA 
(n=25) 
2/25 
(8%) 
4/25 
(16%) 
17/25 
(68%) 
1/25 
(4%) 
1/25 
(4%) 
0.898 
NEPHROTIC 
RANGE (n=13) 
2/13 
(15.4%) 
2/13 
(15.4%) 
8/13 
(61.5%) 
0/13 
(0%) 
1/13 
(7.7%) 
0.492 
HAEMATURIA 
(n=21) 
2/21 
(9.5%) 
3/21 
(14.3%) 
15/21 
(71.4%) 
0/21 
(0%) 
1/21 
(4.8%) 
0.942 
PYURIA (n=19) 
2/19 
(10.5%) 
4/19 
(21%) 
13/19 
(68.4%) 
0/19  
(0%) 
0/19 
(0%) 0.514 
URINARY 
CASTS (n=6) 
1/6 
(16.7%) 
1/6 
(16.7%) 
3/6 
(50%) 
0/6 
(0%) 
1/6 
(16.7%) 
0.178 
HTN (n=6) 
2/6 
(28.6%) 
0/6 
(0%) 
5/6 
(71.4%) 
0/6 
(0%) 
0/6 
(0%) 0.345 
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Figure 11: Comparison of laboratory parameters with classification of lupus 
nephritis 
Class IV lupus nephritis group was reported in 61.5% with nephrotic range proteinuria, 
71.4%  in those with haematuria, 71.4% in those with hypertension, 68.4 % in  those 
with pyuria  and 50% in those with urinary casts.  
None of these were statistically significant. 
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10) Clinical characteristics of Lupus nephritis group 
 
Table 12 : PARAMETERS AMONG LUPUS NEPHRITIS GROUP 
 
 
C3 and C4 levels were significantly lower in the newly diagnosed group compared with 
those on treatment (with relapse or remission) (p value < 0.05).  
Differences of other comparisons in these groups of laboratory parameters and blood 
pressure were not statistically significant.  
Most newly diagnosed patients were on prednisolone. Only 2 newly diagnosed lupus 
nephritis patients and a significant number of old patients were on Mycophenolate 
mofetil. 
PARAMETERS NEWLY DIAGNOSED 
(n = 13) 
RELAPSE 
(n = 21) 
REMISSION 
(n = 6)  
p value 
Ds DNA 
 
492 ± 307.6 379.2 ± 385.64 32.67 ± 32.44 0.14 
Urine protein 
creatinine ratio 
2.62 ± 2.47 3.11 ± 3.11 0.07± 0.04 0.06 
C3 44.2 ± 31.1 65.14 ± 36.78 98.07 ± 24.31 0.009 
C4 9.0 ± 4.9 13.85 ± 9.28 19.38 ± 9.01 0.039 
Creatinine 0.7 ± 0.2 0.74 ± 0.43 0.57 ± 0.02 0.556 
Blood pressure  
Systolic BP 
Diastolic BP 
 
114.8 ± 23.3 
73.2 ± 15.3 
 
 
120.29 ± 16.98 
74.67 ± 17.17 
 
102.5 ± 10.73 
67.83 ± 16.59 
 
0.131 
0.674 
Treatment (%) 
Prednisolone 
Mycophenolate 
mofetil 
 
 84.6% 
15.4% 
 
76.2% 
57.1% 
 
50% 
66.7% 
 
 
0.265 
0.03 
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11) Comparison of laboratory parameters   
 
Table 13 : LABORATORY PARAMETERS BETWEEN LUPUS NEPHRITIS AND  
   SLE WITHOUT NEPHRITIS 
VARIABLES LUPUS NEPHRITIS 
 (n = 40) 
MEAN ± SD 
SLE WITHOUT 
NEPHRITIS  
(n = 36) 
MEAN ± SD 
MEAN 
DIFFERENCE 
p  VALUE 
Anti ds DNA 363.5± 357 245.3 ± 232.3 118.2 0.33a 
C3 63.2 ± 13.1 82.6 ± 5.5 - 19.4 0.02 
C4 13.1 ± 8.6 11.3 ± 5.3 1.8 0.3 
Urine protein/ 
Creatinine ratio 
2.5 ± 2.8 0.2 ± 0.3 2.3 <0.001 
Creatinine 0.7 ± 0.3 0.5 ± 0.08 0.2 0.002a 
Hypertension SBP = 115.8 ± 19.2 
DBP = 73.2 ± 16.2 
SBP = 104.7 ± 10.2 
DBP = 64.1 ± 10.1 
11.1 
9.1  
0.003 
0.005 
a
 Mann-Whitney U test was used to assess the significant difference 
C3 levels, urine protein creatinine ratio and serum creatinine levels showed significant 
difference between Lupus Nephritis and SLE patients without Nephritis ( p= < 0.05) 
 Systolic and diastolic blood pressure was found to be significantly higher among 
Group 1a  Lupus Nephritis patients (p value < 0.05) 
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12)  Medications  
 
Table 14 : MEDICATION PROFILE 
MEDICATIONS LUPUS NEPHRITIS 
 n= 40 (%) 
SLE WITHOUT 
NEPHRITIS 
n = 36 (%) 
PREDNISOLONE 30/40 (75%) 20/36(55.5%) 
HYDROXYCHLOROQUINE 32 /40(80%) 28/36 (77.7%) 
MYCOPHENOLATE MOFETIL 18/40 (45%) 2 /36(5.5%) 
AZATHIOPRINE 8/40 (20%) 3/36 (8.3%) 
CYCLOPHOSPHAMIDE 4/40 (10%) 0 
OTHERS 3/40 (7.5%) 0 
 
30
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LUPUS NEPHRITIS SLE
                                             Figure 12: MEDICATIONS 
A total of 75% (30 /40) of the patients with lupus nephritis were on corticosteroids as 
compared to 55.5% of SLE patients (20/36).  
The most commonly used second line drug in both groups was hydroxychloroquine. 
Mycophenolate mofetil were more commonly used among Lupus nephritis as compared 
to SLE patients (45% versus 5.5%). 
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PART III: URINARY TWEAK LEVELS BETWEEN GROUPS IN THE 
COHORT 
 
URINARY TWEAK BETWEEN LUPUS NEPHRITIS, SLE without nephritis 
AND HEALTHY CONTROLS 
Urinary TWEAK levels were done among the four groups – Group Ia, Ib, disease 
controls and healthy controls. The results were analysed and compared among the four 
groups and also with other laboratory parameters. Urinary TWEAK level was also 
correlated with the classification of lupus nephritis as well as renal disease activity 
which is described by renal SLEDAI score of ≥ 4.  
 
Table 15 : Urinary TWEAK level 
Variable Median Mean+ STD Range 
Urinary TWEAK     3.32 3.49 + 2.29 0.02 – 10.35 
 
The mean level of Urinary Tweak levels for the cohort was 3.49 ± 2.29 ng/ml, ranging 
from 0.02 to  10.35 ng/ml. 
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13)  Urinary TWEAK levels between study groups 
 
The box plot of the comparison is shown in Figure 13.Statistical tests to ascertain 
significance was done between groups using one-way ANOVA. 
Table 16 : Urinary TWEAK between different groups 
GROUP URINARY TWEAK 
LEVEL(MEDIAN) 
MEAN ± SD p VALUE 
LUPUS NEPHRITIS(Gp 1a) 3.17 3.26 ± 2.55  
 
 
0.888 
SLE WITHOUT 
LUPUS NEPHRITIS(Gp 1b) 
3.47 3.47 ± 2.18 
AUTOIMMUNE/ RENAL (Gp II) 3.42 3.67 ± 2.44 
HEALTHY CONTROLS(Gp III) 3.03 3.63 ± 2.12 
 
 
 
Figure 13: Comparison of urinary TWEAK between different groups 
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The Urinary TWEAK levels were highest in the SLE without Nephritis group, closely 
followed by the Autoimmune /Renal disease group. The SLE with nephritis group had 
lower values, but was higher than the healthy controls. However, the difference 
between these groups was not statistically significant. (p value = 0.888).  
14) Comparison between renal SLEDAI score and urinary 
TWEAK levels 
 
One-way ANOVA was used for assessing the significant difference between the renal 
SLEDAI scores. 
 
 
Figure 14: Comparison between renal SLEDAI and urinary TWEAK levels 
Higher renal SLEDAI score had a higher median value of urinary TWEAK. However 
the difference was not statistically significant (p = 0.743). 
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15)  TWEAK levels and class of lupus nephritis  
 
 
Figure 15: Comparison of urinary TWEAK levels between lupus nephritis classes 
Maximum levels of TWEAK were seen in Class III (focal) followed by class II 
(mesangial) and class IV (diffuse) lupus nephritis.  
This difference was not statistically significant (p – 0.489). 
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16)  Urinary TWEAK levels and ds DNA antibodies  
 
A Pearson’s Correlation was run to assess the correlation between Urinary TWEAK 
levels and ds DNA antibodies. 
 
 
Figure 16: Comparison of urinary TWEAK levels with anti ds DNA antibodies  
There was negligible positive correlation between TWEAK levels and ds DNA 
antibodies with r = 0.07. The correlation was not statistically significant (p = 0.686). 
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17) Urinary TWEAK levels and serum creatinine 
 
Pearson’s correlation was used to assess correlation between urinary TWEAK and 
serum creatinine levels. 
 
 
Figure 17: Comparison of urinary TWEAK levels and serum creatinine  
 
There was a small negative correlation between the serum creatinine levels and urinary 
TWEAK levels.  
However this was not statistically significant (p= 0.234, r = - 0.19) 
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18) Urinary TWEAK levels and urine protein creatinine 
ratio 
 
Pearson’s correlation method was used for analysis 
 
 
 
Figure 18: Comparison of urinary TWEAK levels with urine protein creatinine 
ratio  
The correlation coefficient for urine protein creatinine ratio was 0.2, indicating a 
positive correlation; this was not statistically significant (p= 0.228). 
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19) Urinary TWEAK levels and  complement C3 levels 
 
 
Figure 19: Comparison of urinary TWEAK levels and complement C3 
level 
There was a negative correlation between TWEAK levels and C3 (r = -0.21, p = 0.21). 
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20) Urinary TWEAK levels and complement C4 levels 
 
 
Figure 20: Comparison of urinary TWEAK levels and complement C4 
levels 
 
There was a negative correlation between TWEAK levels and C4 (r = -0.06, p = 0.72). 
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21)  Sensitivity and Specificity of TWEAK levels  
 
 
Figure 21: ROC curve for sensitivity and specificity of urinary 
TWEAK  
ROC curve was plotted for determining the sensitivity and specificity 
The area under the curve was 0.46. 
The sensitivity of TWEAK for determining the disease activity was 60.53% and the 
specificty was 36.11%. 
The cut off value for determining the active disease was reported as  ≥  2.7 ng/ml 
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DISCUSSION 
This prospective study was done to assess the utility of urinary TWEAK for diagnosis 
of lupus nephritis and its correlation with other markers of lupus nephritis. The study 
was conducted in the Department of Child Health (Paediatric Nephrology and 
Rheumatology divisions) at Christian Medical College, Vellore.  
There were 156 children enrolled in the study (40 in lupus nephritis, 36 in SLE without 
nephritis, 40 in other autoimmune and renal disease and 40 in healthy control groups)- 
all of whom fulfilled the Inclusion criteria and had none of the exclusion criteria. 
Demography, clinical presentations and laboratory parameters were further analysed 
among patients with Lupus nephritis and those SLE without nephritis.  
Demographic characteristics  
SLE is an autoimmune disease which predominantly affects women of child bearing 
age and young female adolescents. According to literature, about 15-20% of SLE cases 
are seen among children less than 18 years of age (1,32,33,55). 
In our study, the median age of SLE patients was 14 years- both in the Lupus Nephritis 
group (Goup 1 a) and those without renal involvement)( Group 1b). The age 
distribution was slightly higher when compared to other Indian studies.  In Agarwal et 
al study (8), the mean age group of SLE was reported to be  10.5 year  while  Singh et 
al (30)reported  10 years. Many of the patients in our study had been treated for varying 
duration prior to presentation and subsequently referred to our centre at a later stage of 
the disease. The higher mean age may be due to delayed diagnosis or due to poor 
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response to therapy in our institution we now see children up to 18 years of age. All 
these reasons may account for a higher mean age in our study population.  
Timing of renal biopsy may have also resulted in a higher mean age. Initially, all 
children with SLE in our institution underwent renal biopsy at the time of presentation, 
irrespective of any clinical or laboratory indicators of renal involvement. However over 
the last few years the practice has changed. Currently renal biopsy is done only in 
patients with definite features of renal involvement as indicated by presence of 
proteinuria, haematuria, pyuria, urinary cast, hypertension and elevated creatinine. This 
change in our institution protocol may have contributed to the higher mean age group 
among lupus nephritis as the children are older.  
SLE disease is a disease with female preponderance. In our study we also had a female: 
male ratio of 1:3.4 in lupus nephritis group and 1: 2.6 in SLE group. It was comparable 
to Western studies (35) but was lower when compared to other Asian countries. Huang 
JL et al, 2004 reported prevalence among girls to be  6.2 times higher than those among 
boys (57). A study done in our own institution by Agarwal et al, 2009 reported a  male : 
female ratio of 1:6 (8). However Singh et al (83) reported a  similar sex distribution to 
our study (male : female ratio of 1:4). Whether this lower female: male ratio in our 
study is due to the fact that lesser number of female children are being brought to 
medical attention is not known. 
In our study, body mass index among SLE and Lupus nephritis groups were higher (19 
versus 18.4) when compared to healthy children. Most of the children with SLE and 
lupus nephritis groups are on prolonged steroid therapy which could explain the higher 
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body mass index in this group of patients. Previous studies have not looked into the 
body mass index among this group of patients nor have they compared with normal 
healthy children. 
In our study, the median duration of disease in lupus nephritis patients was higher than 
that in patients with SLE without lupus nephritis (24 months versus 17 months). Similar 
finding was shown by Singh et al with onset to lupus nephritis occurring 9.4 ± 12.6 
months after the initial diagnosis of SLE (83). As discussed earlier, this late 
presentation of lupus nephritis may be due to delayed diagnosis, late referral to a 
tertiary centre like ours or renal biopsy being done only after the clinical evidence of 
renal invlovement.  
Clinical manifestations  
Clinical features (based on 1997 ACR classification) of SLE were compared between 
the   Group Ia and Group Ib patients. Both the groups had similar clinical presentation. 
The most common feature was ANA positivity followed by serological evidence of an 
immune disorder. ANA was positive in all SLE patients (100%) but in only 85% of 
lupus nephritis patients. This was comparable to other studies like Mackie et al (35), 
Lee et al (36) and Singh et al (83). Immune disorder as characterized by elevated anti 
Ds DNA was present in 87.5% and 88.9% of patients with Group Ia and Group Ib 
respectively. This was similar to Indian studies (8,83) but lower when compared to 
other Western and Asian countries (35,36).The reason for this difference is unclear. 
The other common non renal manifestations were musculoskeletal followed by 
haematological and mucocutaneous involvement. Musculoskeletal involvement in 
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Group Ia and Group Ib was 63.9% and 70% respectively. This finding was similar to 
Mackie et al (100) and Agarwal et al (8) but was higher compared to other Asian 
countries (25,36,83). The occurrence of haematological involvement was seen in 57.5% 
of Group Ia and 50% in Group Ib patients  which was found to be lower when 
compared to Western study (100) but higher than those reported in other Asian 
countries (25,36,83).  Mucocutaneous involvement like malar rash was comparable 
with other Indian studies (7,8,30) but occurrence of oral ulcers was higher when 
compared to other Asian studies (30,57). Other rarer manifestations included serositis, 
neurological involvement and discoid rash. These were the least common features in 
other studies as well (8,25,30,36,100)  
Table 17 : Comparison of clinical features of SLE in world 
Table 17 shows the different patterns of clinical feature distribution among SLE 
patients across the world 
 
Clinical features 
(%) 
Present 
study 
India 
Agarwal et al 
Singapore 
Tan et al 
Taiwan 
Lee et al 
Australia  
Mackie et al 
ANA positive  100 - 98.4 98.9 100 
Immune disorder 88.9 77.1 90.6 94.1 94 
Arthritis  63.9 65.7 56.3 37 76 
Haematological 50 60 90.6 52.9 77 
Malar rash 52.8 57.1 45.3 66.7 47 
Oral ulcer 36.1  32.8 34.9 17 
Photosensitivity 30.6 51.5 15.6 27.5 31 
Neurological  16.7 21.4 12.5 9.0 3 
Serositis 5.6 2.8 7.8 13.2 14 
Discoid rash 0 0 15.6 3.7 10 
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Renal involvement is one of the most common clinical manifestations of paediatric 
SLE. It is more active in childhood and is one of the major factors determining the 
survival among these children (2,3,10,33,59). Most often found renal involvements are 
nephritic range proteinuria, haematuria, hypertension and renal failure (9, 38, 39) . 
The renal parameters in lupus nephritis were evaluated in our study. The most common 
feature was noted to be proteinuria (72.5%) followed by haematuria and pyuria (60%) 
and urinary casts (15%). This was in keeping with other Asian and Indian studies which 
showed proteinuria to be the most common feature (9,25,36,83). Although urinary 
sediment is supposed to correlate with severity of renal disease, in our study, presence 
of urinary cast was found to be low among lupus nephritis group.  
Lupus nephritis is divided according to the WHO classification into 6 groups based on 
the histopathological changes. It is well known that the most common histological 
lesion is Class IV lupus nephritis. 
In our study, Class IV (Diffuse segmental proliferative glomerulonephritis) lupus 
nephritis was the most common histopathological findings (63%) followed by Class III 
(Focal proliferative glomerulonephritis) lupus nephritis in 12.5% of the patients. This 
similar to  previous Indian studies as well as other Asian studies which showed Class 
IV to be the commonest followed by Class II lupus nephritis (8,9,32,62,83).  
Similar higher occurrence of Class IV and III lupus nephritis was found in Western 
studies also (12, 93). Due to various factors like late referral to tertiary centres, 
histological changes preceding clinical manifestations, renal biopsy being done only 
after the presence of renal manifestations, late diagnosis of lupus nephritis occurs  and 
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often  more severe  renal damage.  This warrants the need for early screening of 
children with SLE for renal involvement. 
Table 18 : Classification of lupus nephritis in world 
Table 18 shows distribution of different class of lupus nephritis from various 
studies across the world. 
Our study showed   Class IV lupus nephritis group was associated with nephrotic 
range proteinuria (61.5%), haematuria (71.4%), hypertension (71.4%), pyuria 
(68.4%) and urinary casts (50%). Most studies have shown Class IV to be more 
commonly associated with severe renal features like proteinuria and haematuria 
(8,39,62,83). Agarwal et al showed 58.1% proteinuria and 66.6% haematuria in 
class IV lupus nephritis. 
 
Classification 
(%) 
Present 
study 
India 
Agarwal et al 
Singapore 
Tan et al 
Taiwan  
Lee et al 
Australia 
Mackie et al 
CLASS I 0 3.7 0 1 0 
CLASS II 7.5 44.4 0 11.1 0 
CLASS III 12.5 4.3 23.8 11.1 18.1 
CLASS IV  65 44.4 33.3 69.7 72.7 
CLASS V 2.5 1.8 4.8 7.0 9.0 
CLASS VI  2.5       _        _  0  _ 
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Comparison between SLE without nephritis and lupus nephritis groups  
All the laboratory parameters used in the diagnosis of SLE were looked at. This 
included  dsDNA, which is believed to correlate well with renal involvement. However 
comparison of anti ds DNA levels between the two groups Ia and Ib did not show any 
statistically significant difference. This limitation of anti ds DNA level in 
differentiating renal involvement in SLE patients has been described in previous 
literature (13–15).  However both complement C3 level and urine protein creatinine 
ratio showed significant corelation with disease activity among Group Ia patients as 
compared to those in Group Ib (p value < 0.05).  Higher serum creatinine was found 
among Group Ia when compared to Group I b patients (p value < 0.05)- this was also 
statistically significant. Both systolic and diastolic mean blood pressures were also 
significantly elevated among lupus nephritis group (p value < 0.05).  Proteinuria, 
hypertension and elevated creatinine are the known renal parameters which are 
indicative of renal damage.  These parameters have also been found to be present in our 
lupus nephritis group.  
Treatment  
Treatment modalities vary according to regime preference in different centres. In our 
centre corticosteroid was the mainstay of treatment in both Group Ia and Ib patients and 
is  followed in many centres worldwide (8,11,35,83,101).  The second most common 
second line drug was hydroxychloroquine as medication. Studies have shown good 
results in lupus nephritis following the use of Mycophenolate mofetil(11,101,102). The 
use of this drug in  patients in our own institute has increased over the last 6 years (8) 
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URINARY TWEAK ANALYSIS  
Urinary TWEALK was analyzed using Human TWEAK ELISA KIT. Urinary levels of 
TWEAK were compared between the four groups: lupus nephritis, SLE without 
nephritis, autoimmune/renal diseases and healthy controls. 
The mean level was reported to be 3.19 ± 2.2 ng/ml. 
The mean urinary TWEAK level was 3.47 ± 2.18 in SLE without nephritis and 3.26 ± 
2.55 in lupus nephritis group. Group II (Autoimmune and Renal) was 3.67 ± 2.44. 
Surprisingly, the TWEAK levels were highest in the disease control group, closely 
followed by the SLE and Lupus Nephritis groups. The difference however was not 
statistically different (One-way ANOVA analysis- p = 0.888 ) suggesting that urinary 
TWEAK increases in inflammatory conditions but is not specific for SLE patients( both 
renal and non renal). Kralisch et al (98)  found lower levels of serum TWEAK in 
patients with end stage renal disease (p value <0.05), he did not study autoimmune 
diseases hence his study cannot be used as a comparison. Similarly serum TWEAK 
levels were found to be significantly lower in haemodialysis patients as compared to 
healthy individuals (208 versus 461 pg/ml, p < 0.0001) in Carrero et al study(99). 
Schwartz et al (24) had a  finding of lower levels of serum TWEAK in SLE patients 
than in healthy controls. (15.87 vs 23.56, p value < 0.05).In our study group, TWEAK 
levels were slightly higher in our SLE patients compared to healthy controls. 
Schwartz et al (24) study had also reported that urinary TWEAK levels were equally 
good as serum TWEAK levels for diagnosis of lupus nephritis. Hence, though in our 
study urinary TWEAK rather than serum TWEAK was analysed, our results can be 
compared with Schwartz et al. 
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Contrary to our hypothesis, we found urinary TWEAK levels to be lower in lupus 
nephritis patients than in SLE without nephritis patients. Further, it was even lower than 
those with other autoimmune/ renal disease. The reason for this difference from 
Schwartz study is unclear.   
Schwartz study, the only study with a similar methodology as ours reported urinary 
TWEAK to correlate well with Lupus Nephritis. Our study is not able to corroborate 
this result. No other study is available in literature for comparison. No data is available 
for children. Hence we may postulate that further studies are required to test the validity 
of this marker as a screening test in Lupus Nephritis, and more so in children.  
TWEAK VERSUS RENAL SLEDAI  
Correlation of urinary TWEAK levels with renal SLEDAI score showed that a higher 
renal SLEDAI score had a higher median value of urinary TWEAK. Though the values 
were not statistically significant (p = 0.743) it may be suggested that Urinary TWEAK 
could be a marker for activity in Lupus Nephritis, just as shown by Xueling et al and  
Schwartz et al study(24) who were able to show a positive correlation between renal 
SLEDAI score and urinary TWEAK levels ( p <0.001).  
In our study we were able to recruit 38 children with Lupus Nephritis. Hence a study 
with as larger sample size, having adequate number of children with active and inactive 
disease needs to be done in order to see whether it is a good differentiating test for these 
conditions. 
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COMPARISON OF URINARY TWEAK LEVELS BETWEEN LUPUS NEPHRITIS 
CLASSES 
The urinary TWEAK levels were compared with different classes of lupus nephritis 
with the assumption that there will be a positive correlation between the two variables 
since more renal inflammation and damage is associated with higher class of lupus 
nephritis. In our study, it was seen that the maximum levels of TWEAK levels were 
seen in Class III followed by Class II and much lower in IV lupus nephritis. Though the 
difference was not statistically significant (p – 0.489), it goes against our proposed 
hypothesis that TWEAK is involved in inflammatory responses especially in renal 
tissues.  It is possible that the unequal distribution of patients in each class of lupus 
nephritis and the overall small number of patients could not give us a significant 
correlation. Schwartz et al study (24), urinary TWEAK level was also not able to 
discriminate between the histological class of lupus nephritis.  
CORRELATION BETWEEN URINARY TWEAK LEVELS AND ANTI dsDNA 
ANTIBODIES   
Urinary TWEAK levels were compared against the currently available parameters used 
to assess the disease activity. 
 A Pearson’s Correlation was run to assess the correlation between Urinary TWEAK 
levels and ds DNA antibodies. There was positive correlation between urinary TWEAK 
levels and anti ds DNA antibodies but the correlation was not found to be statistically 
significant (p = 0.686). The correlation coefficient with urine protein creatinine ratio 
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was 0.2 indicating a positive correlation with renal involvement. However the 
correlation was not statistically significant (p= 0.228). 
A small negative correlation was found between serum creatinine levels and urinary 
TWEAK levels, however the correlation was not statistically significant (p= 0.234, r = -
0.19). There was a negative correlation between TWEAK levels and both complement 
C3 and C4 levels (r = -0.21 and -0.06 respectively). However, the correlation among 
these two levels was also not strong. 
Thus, when used alone, urinary TWEAK level showed a positive correlation with anti 
ds DNA and  Urine Protein Creatinine ratio and a negative correlation with  Serum 
Creatinine and C3 levels.  This suggests that TWEAK would be a better screening test 
rather than a diagnostic Test. It is no better than Ds DNA and C 3, C4 levels and Urine 
Protein Creatinine ratio which are the current tests in use. The negative correlation with 
creatinine suggests that TWEAK levels may start declining once renal function starts 
worsening.  
A ROC curve was plotted for determining the sensitivity and specificity of Urinary 
TWEAK as a diagnostic test.The area under the curve was 0.46.The sensitivity of 
TWEAK for determining the disease activity was 60.53% and the specificity was found 
to be 36.11%.The cut off value for determining the active disease was found to be more 
than 2.7 
Further studies on this Biomarker may be undertaken to give a clearer picture about the 
suitability of TWEAK as a biomarker for SLE patients. 
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SUMMARY  
1) A total of 156 children who fulfilled the inclusion criteria were recruited for tis 
study (40 in lupus nephritis, 36 in SLE, 40 in disease control and 40 in healthy 
children group)  
2) The median age for lupus nephritis group and SLE without nephritis group was 
14 whereas it was 12.5 in the disease control group (other autoimmune and renal 
disease) and 8 in healthy controls. 
3) Both lupus nephritis (Ia) and SLE without nephritis (Ib) groups had female 
preponderance with male : female ratio of  1 : 3.4 in group Ia and 1 : 2.6 ratio in 
group Ib . 
4) Both Ia and Ib groups had higher body mass index of 19 and 18.4 respectively as 
compared to disease control and healthy control children. 
5) Median duration of disease in group Ia patients was 24 months and 17 months in 
group Ib. 
6) Both group Ia and Ib patients had similar clinical features. ANA was positive in 
all SLE patients (100%) as compared to 85% among lupus nephritis patients. 
Immune disorder as characterized by elevated anti ds DNA were in 87.5% and 
88.9% of patients with Group Ia and Group Ib respectively.  Common non renal 
manifestations were musculoskeletal (Group Ia 63.9% and Group Ib  70% ) 
followed by haematological( 57.5% in  Group Ia and 50% in Group Ib) and 
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mucocutaneous involvement. Other rarer manifestations include serositis, 
neurological involvement and discoid rash.  
7) Among the renal parameters in group Ia, majority had proteinuria - 29 patients 
(72.5%) followed by 24 patients (60%) each with haematuria and pyuria. Only 6 
patients (15%) had urinary casts.  
8) 13 patients (32.5%) had renal SLEDAI score of twelve followed by 8 patients 
(20%) with renal SLEDAI score of four. Renal SLEDAI score was not available 
for one patient 
9) Of the total, 65% (26/36) of the patients had Class IV Lupus nephritis (Diffuse 
proliferative GN) followed by Class III Lupus ( Focal proliferative GN) nephritis 
in 12.5% (5/36) 
10) Class IV lupus nephritis were accounted for most of the cases of nephrotic range 
proteinuria (61.5%), haematuria (71.4%), hypertension (71.4%), pyuria (68.4%) 
and urinary casts (50%).  
11) Among laboratory parameters only complement levels C3 and C4 were 
significantly assocaited with the newly diagnosed, relapse and remission patients 
in group Ia (p value < 0.05).  
12) Higher percentage of patients with relapse and remission were on 
mycophenolate mofetil as compared to newly diagnosed lupus nephritis. Most 
newly diagnosed patients were on prednisolone.  
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13) Among the laboratory parameters, complement C3 levels, urine protein 
creatinine ratio and serum creatinine levels showed significant difference 
between Group I a and Group Ib patients with p value < 0.05. 
14) Systolic and diastolic blood pressure was found to be higher among Group Ia 
patients (p value < 0.05) 
15) 30 patients 75% of the patients (30/40) with lupus nephritis were on 
corticosteroid as compared to 55.5% of SLE patients (20/36). The most 
commonly used second line drug in both groups was hydroxychloroquine. 
Mycophenolate mofetil were more commonly used among lupus nephritis as 
compared to SLE patients (45% versus 5.5%). 
16) 134 children from four different groups (38 in lupus nephritis, 36 in SLE 
without nephritis, 40 in healthy control and 21 in disease control) were tested for 
urinary TWEAK levels. 
17) The mean level of Urinary Tweak levels  was 3.49 ± 2.29 ng/ml, ranging from 
0.02 to 10.35 ng/ml 
18) The Urinary TWEAK levels were highest in the SLE without Nephritis group, 
closely followed by the Autoimmune /Renal disease group. The SLE Nephritis 
group had lower values, but was higher than the Healthy Controls. However, the 
difference between these groups was not statistically significant. (p value = 
0.888).  
95 | P a g e  
 
19) Higher renal SLEDAI score had a higher median value of urinary TWEAK. 
However the values were not statistically significant (p value 0.174). 
20) Maximum levels of TWEAK levels were seen in Class III followed by Class II 
and then by IV lupus nephritis. The difference was not statistically significant (p 
= 0.174).  
21) There was mild positive correlation between TWEAK levels and anti ds DNA, 
and urine protein creatinine ratio. The difference was not  statistically 
significant(p > 0.05)  
22) There was negative correlation between urinary TWEAK levels and serum 
creatinine and  complement C3 and C4 levels but it was not statistically 
significant (p > 0.05) 
23) The ROC plot showed an Area under the curve of  0.46. The sensitivity of 
TWEAK for determining the disease activity was 60.53% and the specificty was 
found to be 36.11%.  
24) The cut off value for determining the active disease was >  2.7 ng/ml. 
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CONCLUSIONS 
1. Urinary TWEAK levels among paediatric age group could not differentiate lupus 
nephritis patients from SLE patients without renal involvement.  
2. Urinary TWEAK levels were also elevated in children with other Autoimmune /renal 
diseases hence could not differentiate between SLE and non SLE patients. 
3. Urinary TWEAK had a positive correlation with renal SLEDAI score hence may be 
considered to show promise as a marker of activity in Lupus Nephritis. 
3. The TWEAK levels were not able to differentiate between the different Classes of 
Lupus Nephritis. 
4.Urinary TWEAK had a sensitivity of 60.53% and specificty of 36.11% for diagnosing 
Lupus Nephritis among SLE patients. Hence it may be a better screening test rather 
than a diagnostic test. 
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LIMITATIONS 
1. Majority of the patients in lupus nephritis group were already on corticosteroids or 
second line of immunomodulators. Whether prior doses of steroids significantly reduce 
the levels of urinary TWEAK is not known.  
2. Larger and longitudinal studies would be helpful to know the progression of urinary 
TWEAK over time in relation to its renal disease in lupus nephritis. 
3. Urinary TWEAK levels were lower than expected in the disease group (lupus 
nephritis and SLE without nephritis) as compared to other autoimmune and renal 
disease group. Whether this was due to timing of specimen collection is not known. 
 4. Whether healthy controls in general have relatively higher levels of urinary TWEAK 
is not known. This finding needs further evaluation.   
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RECOMMENDATIONS 
Further studies among paediatric population with larger sample size of Lupus Nephritis 
patients are needed to re-evaluate the usefulness of urinary TWEAK as a test.  
Other new emerging biomarkers for diagnosis of lupus nephritis need to be studied to 
assess their correlation with disease activity and class of lupus nephritis. 
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ANNEXURE II 
                                    PARTICIPANT INFORMATION SHEET 
Christian Medical College, Vellore 
Department of Child Health II 
Role of urinary TWEAK as a biomarker in children with Lupus Nephritis 
You are being requested to allow your child to participate in a study to evaluate the 
effectiveness of urinary TWEAK, a new test for involvement of kidney in lupus 
nephritis. Studies have shown that this new test is a better marker than the standard test 
available.Urine sample for all children with suspected SLE will be collected and 
analyzed. Results will be correlated with the standard test which suggests kidney 
involvement. We will also check this marker in normal children as well as children with 
other forms of kidney disease and autoimmune diseases. If we find increase in level of 
TWEAK in SLE children with kidney involvement, it will serve as an early marker and 
help in early intervention. Participation in this study involves giving urine specimen for 
this study and blood sample for future studies (optional) both of which are easy test to 
perform without any complications.All details including personal data and assessment 
of the doctor will be kept confidential. Participation is purely voluntary, and you can 
withdraw your child from the study at any time and that refusal to participate will not 
involve any penalty or loss of benefits to which your child is otherwise entitled. 
In case of doubts/questions, please contact Dr Muniya Thokchom, Department of Child 
Health, CMCH, Vellore, phone no. 9597863326 
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INFORMED ASSENT FORM 
Christian Medical College, Vellore 
Department of Child Health II 
Role of urinary TWEAK as a biomarker in children with Lupus Nephritis 
STUDY NUMBER:                                        NAME:                                                             
 AGE:                                                             SEX: 
 PHONE NUMBER:                                      ADDRESS: 
1) I confirm that I have read and understood the information sheet for the 
above the study and have had the opportunity to ask questions. 
2) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. 
3) I understand that the Principal investigator, the Ethics committee and the 
regulatory authorities will not need my permission to look at my health 
records both in respect of the current study and any further research that 
may be conducted in relation to it, even if I withdraw from the trial. I agree 
to this access. However I understand that my identity will not be revealed 
in any information released to the third parties or published. 
4) I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purposes. 
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5) I understand that this study involves only urine specimen but blood 
specimen will also be collected simultaneously which may be used for 
related studies later in future. 
a) I am willing to give both urine and blood specimen for this study  
 OR 
I am willing to give only urine sample for this study  
 
6) I agree to take part in the above study. 
 Signature of the subject: 
 Signatory’s name:                                                                        Date: 
 Thumb impression:                  
 
  Signature of the parent/legally acceptable representative: 
  Signatory’s name:                                                                        Date:  
  Thumb impression:                           
 
  Signature of the Investigator: 
  Study Investigator’s name:                                                         Date: 
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INFORMED CONSENT FORM 
Christian Medical College, Vellore 
Department of Child Health II 
Role of urinary TWEAK as a biomarker in children with Lupus Nephritis 
STUDY NUMBER:                                        NAME:                                                             
 AGE:                                                                SEX: 
 PHONE NUMBER:                                      ADDRESS: 
1) I confirm that I have read and understood the information sheet for the 
above the study and have had the opportunity to ask questions. 
2) I understand that the participation of my child in the study is voluntary and 
that I am free to withdraw at any time, without giving any reason, without 
my child’s medical care or legal rights being affected. 
3) I understand that the Principal investigator, the Ethics committee and the 
regulatory authorities will not need my permission to look at my child’s 
health records both in respect of the current study and any further research 
that may be conducted in relation to it, even if I withdraw my child from the 
trial. I agree to this access. However I understand that my child’s identity 
will not be revealed in any information released to the third parties or 
published. 
4) I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purposes. 
5) I understand that this study involves only urine specimen but blood 
specimen will also be collected simultaneously which may be used for 
related studies later in future. 
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a) I am willing to let my child give both urine and blood specimen 
for this study  
 OR 
b) I am willing to let  my child give only urine sample  for this study  
 
6) I agree to let my child take part in the above study. 
  Signature of the parent/legally acceptable representative: 
  Signatory’s name:                                                                        Date:  
  Thumb impression:  
 
 
  Signature of the Investigator: 
  Study Investigator’s name:                                                         Date: 
 
 
 Signature of the witness:                                                                                       
 Witness’ name:                                                                               Date: 
Thumb impression:  
 
115 | P a g e  
 
ANNEXURE III 
CASE REPORT FORM 
Role of urinary TWEAK as a biomarker in children with Lupus Nephritis 
Serial number:                                       Date   
Name:                                    Hospital number                                Age             Sex                 
Height:                    Weight:                                             BMI   
Phone number:                                   Address                                                   
 Group   :  
Lupus nephritis (Ia) SLE with LN (Ib) Autoimmune /other 
renal diseases 
Healthy controls 
    
Disease duration                                          Renal biopsy (WHO classification) :  
1982 ACR criteria for SLE  
Malar rash Renal disorder 
Discoid rash Neurological disorder 
Photosensitivity Hematological disorder 
Oral ulcers Immune disorder 
Non erosive arthritis  Positive ANA 
Serositis  
SLEDAI SCORE:                                                                  TOTAL SCORE:  
8 SEIZURES  
8 PSYCHOSIS  
8 ORGANIC BRAIN SYNDROME  
8 VISUAL DISTURBANCE  
8 CRANIAL NERVE DISORDER  
8 LUPUS HEADACHE  
8 CEREBROVASCULAR ACCIDENTS  
8 VASCULITIS  
4 ARTHRITIS  
4 MYOSITIS  
4 URINARY CASTS  
4 HAEMATURIA  
4 PROTEINURIA  
4 PYURIA  
2 NEW RASH  
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2 ALOPECIA  
2 MUCOSAL ULCERS  
2 PLEURISY  
2 PERICARDITIS2  
2 LOW COMPLEMENT  
2 INCREASED DNA BINDING  
1 FEVER  
1 THROMBOCYTOPENIA  
1 LEUKOPENIA  
 
Renal SLEDAI SCORE:                                                      TOTAL SCORE:  
4 URINARY CASTS  
4 HAEMATURIA  
4 PROTEINURIA  
4 PYURIA  
EXAMINATION:  Blood pressure:                           95
th
 centile for the age/sex :                  
INVESTIGATIONS: 
Urine routine and 
microscopy 
Anti ds DNA 
antibodies 
UP/UC  Urine 
TWEAK 
Renal biopsy 
RBCs :     
WBCs :     
Proteinuria:     
Casts :     
 
Haemoglobin WBC Platelets Creatinine C3 C4 
levels 
     
 
TREATMENT: 
                                  Drug Duration  
Steroid :   
Immunomodulator :   
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ANNEXURE IV 
Human TWEAK ELISA kit 
ASSAY PROCEDURE 
1) 100 microL of sample or standard was added to the appropriate number of 
wells in the supplied Neoplate. 100microL of PBS (pH 7.0 – 7.2) to the blank 
well was added 
2) 50 microL of enzyme solution to each well in the supplied neoplate was added 
and mixed well 
3) Neoplate was covered and incubated for 1 hour at 37’C in a humid chamber 
4) Each well is washed 5 times with 300 – 400 microL 1X wash well per well. 
After the last wash the plates is inverted and blot dry by tapping on absorbent 
paper. 
5) 50 microL of substrate A was added to each well followed by addition of 50 
microL of substrate B. It is then covered and incubated 10 -15 minutes at 
room temperature. 
6) 50 microL of stop solution is added to each well and mixed well 
7) Optical density (O.D) is read immediately at 450nm 
8) The mean blank value from each sample or standard value is subtracted and 
the mean for duplicate wells is calculated 
9) The standard curve is constructed using graph paper or statistical software 
 
 
 
 
sno date age sex ht wt bmi grp ddur rbiop malar dis photosens oral arthritis serositis renal neuro haemat immune ana acr sledai
2 1/23/2015 18 1 179 85 26.6 1 60 4 FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 1 0
3 7/30/2015 10 2 140 38 19.3 1 6 4 FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE TRUE TRUE 5 23
4 7/29/2015 14 1 154 45 19.2 1 30 4 TRUE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE TRUE TRUE 6 24
5 7/20/2015 15 2 162 84 32.1 1 36 4 TRUE FALSE FALSE TRUE FALSE FALSE TRUE FALSE TRUE TRUE TRUE 6 25
6 7/17/2015 8 2 109 18 15.8 1 12 0 TRUE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE TRUE TRUE 6 35
7 7/10/2015 14 2 149 48 21.5 1 24 4 TRUE FALSE FALSE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE 7 20
8 7/17/2015 14 2 158 38 15.3 1 7 2 TRUE TRUE FALSE TRUE TRUE TRUE TRUE FALSE TRUE TRUE TRUE 9 29
9 7/10/2015 14 2 151 50 21.8 1 15 3 FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE FALSE TRUE TRUE 4 24
10 7/3/2015 13 2 142 31 15.4 1 1 0 FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE TRUE TRUE 4 12
11 5/1/2015 13 1 144 31 14.9 1 21 4 FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 1 14
12 7/8/2015 12 2 138 39 20.5 1 2 4 FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE TRUE TRUE 4 22
13 12/24/2014 16 2 158 47 18.8 1 35 3 TRUE FALSE FALSE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE 7 26
14 9/2/2015 11 2 143 30 14.8 1 1 4 FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE FALSE TRUE TRUE 4 23
15 4/11/2015 13 2 163 49 18.6 1 9 4 TRUE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE TRUE TRUE 6 28
16 5/6/2015 9.5 2 121 23 16.1 1 3 0 TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE TRUE TRUE 6 18
17 5/1/2015 14 2 151 40 17.8 1 6 4 TRUE FALSE FALSE FALSE TRUE TRUE TRUE FALSE FALSE TRUE TRUE 6 25
18 6/23/2015 12 2 154 49 20.7 1 1 5 FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE TRUE TRUE 4 13
19 6/5/2015 13 1 143 30 14.8 1 17 3 FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE TRUE TRUE 5 25
20 6/13/2015 18 2 164 60 22.6 1 72 2 FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE FALSE TRUE TRUE 4 14
21 5/1/2015 17 2 144 38 18.2 1 48 4 TRUE FALSE TRUE TRUE TRUE FALSE TRUE FALSE FALSE TRUE TRUE 7 24
22 12/12/2014 16 2 147 34 15.7 1 60 4 FALSE FALSE FALSE FALSE TRUE TRUE TRUE FALSE FALSE TRUE TRUE 5 17
23 5/6/2015 17 1 152 40 17.5 1 48 4 FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE FALSE FALSE 3 18
24 3/6/2015 16 2 155 51 21.1 1 24 3 TRUE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE TRUE TRUE 6 26
25 12/22/2014 15 2 156 52 21.4 1 24 6 FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE TRUE TRUE 4 16
26 4/10/2015 14 2 137 41 22.1 1 27 4 FALSE FALSE TRUE TRUE TRUE FALSE TRUE TRUE TRUE TRUE TRUE 8 10
27 1/23/2015 9 2 128 23 14 1 36 2 TRUE FALSE FALSE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE 7 16
28 3/4/2015 12 1 144 42 20.4 1 36 4 FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE TRUE FALSE 4 11
29 6/19/2015 15 1 159 58 23.1 1 48 4 FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE FALSE TRUE TRUE 4 6
30 6/19/2015 14 2 145 35 16.5 1 22 4 FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE 3 4
31 6/26/2015 14 2 146 46 21.8 1 8 4 TRUE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE TRUE TRUE 6 4
32 6/26/2015 9 2 120 24 16.7 1 4 0 FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE 6 8
33 4/29/2015 14 2 144 48 23.1 1 30 4 TRUE FALSE TRUE TRUE TRUE FALSE TRUE FALSE FALSE FALSE TRUE 6 8
34 6/26/2015 11 1 125 26 16.7 1 84 4 FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE 3 6
35 6/12/2015 11 2 137 42 22.4 1 17 4 FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 1 10
36 6/19/2015 16 2 149 45 20.5 1 17 4 FALSE FALSE TRUE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE 7 0
37 6/19/2015 7 2 123 25 16.5 1 26 4 FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE TRUE FALSE 4 1
38 2/6/2015 13 1 148 36 16.3 1 4 4 FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE 6 4
39 6/24/2015 7 2 144 47 22.7 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
40 6/10/2016 13 2 151 38 16.8 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
41 6/13/2015 10 1 131 26 15.2 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
42 6/10/2015 5 1 111 15 11.8 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
43 6/13/2016 7 2 122 20 13.6 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
44 6/3/2015 12 1 156 45 18.5 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
45 6/24/2015 8 2 133 26 15 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
46 6/20/2015 9 2 115 16 12.1 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
47 6/17/2015 16 2 157 48 19.7 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
48 6/6/2015 15 2 154 42 17.8 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
49 6/20/2015 11 1 145 28 13.2 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
50 6/20/2015 11 1 143 52 25.6 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
51 6/27/2015 6 1 100 13 13 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
52 6/10/2015 7 2 115 18 14.1 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
53 6/10/2015 6 1 119 20 14.3 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
54 6/10/2015 5 1 116 19 14.4 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
55 6/17/2015 13 1 147 32 14.9 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
56 6/6/2015 8 1 135 31 17.3 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
57 6/6/2015 10 1 112 15 12.9 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
58 6/20/2015 13 1 148 53 24.5 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
59 6/6/2015 6 1 107 14 11.9 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
60 6/20/2015 7 1 120 21 14.6 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
61 6/24/2015 14 1 177 80 25.7 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
62 6/6/2015 10 1 131 26 15.2 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
63 6/27/2015 5 1 114 20 15.4 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
65 6/13/2015 15 1 165 45 16.8 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
66 6/27/2015 4 1 104 13 12.4 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
67 6/6/2015 8 1 133 23 13 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
68 6/20/2015 12 1 139 26 13.2 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
69 9/4/2015 9 2 128 27 16.6 2 22 0 TRUE FALSE FALSE TRUE FALSE FALSE FALSE TRUE FALSE FALSE TRUE 4 10
70 6/26/2015 15 2 151 43 18.9 2 11 0 TRUE FALSE TRUE TRUE TRUE FALSE TRUE FALSE FALSE TRUE TRUE 7 16
71 5/1/2015 10 1 126 20 12.8 2 6 0 FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE TRUE TRUE TRUE 4 4
72 6/26/2015 16 2 152 40 17.3 2 18 0 TRUE FALSE TRUE TRUE TRUE FALSE FALSE FALSE TRUE TRUE TRUE 7 15
73 2/20/2015 14 2 155 44 18.4 2 2 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE TRUE 2 14
74 4/10/2015 13 2 150 49 21.7 2 4 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE 2 0
75 6/19/2015 16 1 156 39 16 2 28 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE TRUE 3 4
76 12/24/2014 16 2 153 47 20.2 2 10 0 TRUE FALSE TRUE TRUE FALSE FALSE FALSE FALSE TRUE TRUE TRUE 6 9
77 6/12/2015 12 2 141 42 21.1 2 8 0 TRUE FALSE FALSE TRUE TRUE FALSE FALSE FALSE FALSE TRUE TRUE 5 12
78 1/23/2015 13 1 130 22 13.1 2 6 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE TRUE 2 3
79 6/19/2015 18 2 154 50 21.3 1 74 4 TRUE FALSE FALSE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE 7 0
80 6/19/2015 18 1 55 96 40 2 91 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE 2 0
81 6/20/2015 7 1 113 15 12.4 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
82 6/10/2015 7 1 116 17 13.2 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
83 7/13/2015 6 2 110 14 11.6 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
84 7/13/2015 9 1 111 17 13.6 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
85 8/1/2015 7 2 100 14 14 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
86 8/1/2015 5 1 117 16 11.7 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
87 8/1/2015 7 2 118 16 11.5 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
88 8/1/2015 9 1 128 21 12.8 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
89 8/1/2015 8.5 1 135 39 21.4 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
90 8/1/2015 5.6 2 112 17 13.6 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
91 8/1/2015 7 2 122 24 16.1 4 0 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
92 7/23/2015 17 2 150 84 37.3 2 40 0 FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE TRUE TRUE TRUE 4 12
93 7/14/2015 12 1 138 25 13.1 2 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE TRUE TRUE 3 7
94 8/5/2015 14 2 145 32 15.2 2 17 0 FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE TRUE TRUE TRUE 4 6
95 8/7/2015 11 2 138 38 20 2 6 0 TRUE FALSE TRUE TRUE FALSE FALSE FALSE FALSE FALSE TRUE TRUE 5 6
96 8/1/2015 16 2 149 40 18 2 17 0 FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE TRUE TRUE TRUE 4 14
97 1/23/2015 11 2 127 23 13.9 2 38 0 TRUE FALSE FALSE TRUE FALSE TRUE FALSE FALSE TRUE TRUE TRUE 6 2
98 2/20/2015 15 1 156 45 18.7 2 18 0 TRUE FALSE TRUE FALSE TRUE FALSE FALSE FALSE FALSE TRUE TRUE 5 0
99 12/19/2014 16 2 142 35 17.2 2 51 0 FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE TRUE TRUE TRUE 4 13
100 2/20/2015 13 2 151 49 21.7 2 7 0 TRUE FALSE FALSE TRUE TRUE FALSE FALSE FALSE FALSE TRUE TRUE 5 4
101 4/10/2015 9 1 133 26 14.8 2 3 0 TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE 3 3
102 6/13/2015 15 2 147 42 24.9 2 24 0 TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE TRUE TRUE 4 4
103 4/10/2015 15 2 164 57 21.3 2 8 0 TRUE FALSE TRUE FALSE TRUE FALSE FALSE FALSE FALSE TRUE TRUE 5 18
104 6/5/2015 15 1 161 53 20.4 2 8 0 FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE TRUE TRUE 4 0
105 6/17/2015 9 2 122 26 17.5 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
106 6/26/2015 5 1 99 16 16.3 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
107 2/6/2015 15 2 162 36 14.7 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
108 1/23/2015 15 2 145 31 14.7 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
109 2/6/2015 13 2 125 27 17.3 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
110 12/19/2014 15 1 152 41 17.7 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
111 6/3/2015 4 1 95 14 15.5 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
112 6/13/2015 14 2 158 40 16 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
113 6/3/2015 7 1 121 25 17.1 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
114 6/19/2015 12 2 149 31 14 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
115 2/6/2015 11 1 136 25 13.5 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
116 4/10/2015 17 1 175 59 19.3 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
117 6/19/2015 6 2 106 12 10.7 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
118 6/3/2015 9 1 120 21 14.6 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
119 1/23/2015 16 1 154 36 15.2 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
120 1/23/2015 17 1 161 40 15.4 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
121 12/5/2014 8 1 122 24 16.1 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
122 6/17/2015 16 1 137 34 18.1 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
123 6/5/2015 14 1 140 35 17.9 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
124 6/19/2015 6 1 110 18 14.9 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
125 4/10/2015 17 1 163 56 21.1 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
126 12/19/2014 12 1 132 23 13.2 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
127 12/19/2014 10 1 126 21 13.2 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
128 12/19/2014 12 1 127 25 15.5 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
129 4/10/2015 5 1 100 15 15 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
130 6/17/2015 17 1 143 31 15.2 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
131 6/3/2015 5 1 104 18 16.6 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
132 4/10/2015 6 1 117 22 16.1 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
133 3/6/2015 6 2 110 16 13.2 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
134 2/20/2015 13 1 134 23 12.8 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
135 4/10/2015 15 1 154 30 12.6 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
136 12/19/2014 6 2 108 13 11.1 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
137 6/19/2015 5 1 106 16 14.2 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
138 3/6/2015 15 2 155 57 23.7 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
139 6/3/2015 14 1 153 48 20.5 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
140 1/23/2015 13 2 149 44 19.8 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
141 2/20/2015 16 1 169 52 18.2 3 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
142 7/3/2015 14 2 146 33 15.4 2 26 0 FALSE FALSE TRUE FALSE TRUE TRUE FALSE FALSE FALSE TRUE TRUE 5 0
143 6/13/2015 11 2 135 29 15.9 2 52 0 FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE TRUE TRUE TRUE 4 0
144 9/11/2015 14 2 152 42 18.4 2 3 0 TRUE FALSE TRUE TRUE TRUE FALSE TRUE TRUE FALSE TRUE TRUE 8 14
145 7/3/2015 10 2 147 41 18.9 2 23 0 TRUE FALSE TRUE TRUE TRUE FALSE FALSE FALSE FALSE TRUE TRUE 6 4
146 7/3/2015 12 2 155 58 24 2 22 0 FALSE FALSE FALSE FALSE TRUE FALSE TRUE TRUE FALSE TRUE TRUE 5 16
147 7/31/2015 15 2 152 59 25.4 2 18 0 TRUE FALSE TRUE FALSE TRUE FALSE FALSE FALSE FALSE TRUE TRUE 5 12
148 8/7/2015 18 2 153 40 17.1 2 79 0 TRUE FALSE FALSE TRUE TRUE FALSE FALSE FALSE TRUE TRUE TRUE 6 4
149 8/7/2015 18 2 150 43 18.9 2 54 0 TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE TRUE TRUE 4 6
150 4/10/2015 12 1 145 38 18.3 2 3 0 FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE TRUE TRUE TRUE 4 2
151 6/13/2015 15 2 149 40 18 2 3 0 TRUE FALSE FALSE TRUE TRUE FALSE FALSE TRUE TRUE TRUE TRUE 7 26
152 6/12/2015 17 2 156 62 25.7 2 46 0 FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE TRUE TRUE TRUE 4 5
153 2/20/2015 14 1 156 39 16 3 2 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
154 6/17/2015 7 2 109 16 13.5 3 21 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
155 3/6/2015 14 1 151 51 22.4 3 61 0 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE
157 6/5/2015 17 2 158 40 16 1 34 4 FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE TRUE TRUE TRUE 4 3
158 9/4/2015 12 1 140 27 13.8 2 3 0 TRUE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE TRUE TRUE 5 9
159 8/5/2015 13 2 145 35 26 1 30 3 TRUE FALSE TRUE FALSE FALSE FALSE TRUE FALSE TRUE TRUE TRUE 6 0
ucast hemat pro pyu rsledai sbp dbp sbpcent95 dbpcent95 urbc uwbc protein casts dsdna upuc utweak hb wbc plt crt c3 c4 strds
2 2 2 2 0 110 80 134 82 0 0 0 FALSE 3 0.06 13.7 7700 306000 0.7 123 20.2 0
2 1 1 1 12 100 60 122 80 39 6 2 FALSE 1106 2.2 10.7 4000 321000 0.5 27.9 6.4 40
2 1 1 1 12 114 77 132 84 243 105 3 FALSE 405 8.05 10 9200 205000 0.7 39.7 6.7 60
2 1 1 1 12 150 115 131 85 27 41 3 FALSE 861 1.76 7.4 3300 273000 0.8 76.7 6.2 60
2 1 1 1 12 154 90 118 78 65 53 2 FALSE 441 6 8.7 12900 793000 0.5 91.7 13.6 10
1 1 1 1 16 148 101 129 84 10 6 3 TRUE 168 7.31 11.9 11800 342000 0.5 52.2 6.3 60
1 1 1 1 16 98 54 129 84 7 130 3 TRUE 714 1.72 7.8 5600 214000 0.9 36.4 6.3 40
2 1 1 1 12 106 64 129 84 11 15 1 FALSE 579 3.49 11 6400 333000 0.5 78.1 10.5 40
2 2 1 1 8 113 76 124 81 3 12 2 FALSE 233 0.84 5.8 8300 111000 0.6 17.7 6.2 30
2 1 1 1 12 122 87 130 83 201 96 3 FALSE 2 3.13 9.1 523000 1.1 26 36
1 1 1 1 16 110 70 126 82 571 88 4 TRUE 376 2.39 9 7700 139000 1.2 24.7 22.2 0
2 1 1 1 12 99 60 132 86 12 28 3 FALSE 1035 3.2 7.4 4100 341000 0.5 41 5.9 5
2 1 1 1 12 98 65 124 81 9 39 2 FALSE 676 2.92 12 11800 367000 0.7 34.4 6.4 0
2 1 1 1 12 172 114 128 83 32 86 3 FALSE 759 7.94 8.1 7900 127000 0.9 22.7 5.9 35
2 1 1 1 12 113 78 120 79 9 25 2 FALSE 790 2.22 7.2 4700 186000 0.5 22.1 6.3 20
2 1 1 1 12 122 74 126 82 628 18 3 FALSE 355 5.8 8.9 6800 125000 0.9 17.4 6.3 30
2 2 1 2 4 90 60 126 82 3 3 1 FALSE 250 0.69 6.2 7400 188000 0.5 22.6 6.3 40
1 1 1 1 16 108 60 130 83 7 152 4 TRUE 988 1.45 10.3 4100 299000 0.8 43 10.8 30
2 2 1 1 8 123 85 128 82 2 12 3 FALSE 210 2.04 11.7 5500 398000 0.5 101 15.4 0
1 1 1 1 16 129 83 132 86 9 10 3 TRUE 723 6.77 10.4 4000 185000 0.5 26.2 5.9 40
2 2 1 2 4 126 80 132 86 3 2 2 FALSE 266 4.61 7.2 6900 223000 0.6 30.8 7.3 30
2 1 1 1 12 120 70 137 87 31 40 2 FALSE 0 3.07 1 23.2 34.6 40
2 2 1 1 8 112 82 132 86 4 10 1 FALSE 517 1.19 7.7 5400 312000 0.6 66.2 13.4 20
1 1 1 2 12 128 72 131 85 8 5 3 TRUE 43 1.53 7.7 6200 216000 1.9 89.4 10.4 0
2 1 2 1 8 106 63 129 84 8 14 0 FALSE 162 0.12 11.9 4200 296000 0.5 109 12.4 0
2 1 1 2 8 148 94 115 76 23 2 1 FALSE 1159 1.16 10.1 5600 358000 0.8 16.9 5.8 20
2 1 1 2 8 130 80 127 83 10 5 1 FALSE 0 12.2 10.5 12100 362000 1.8 16.9 8.5 30
2 2 1 2 4 140 80 135 85 2 1 0 FALSE 284 1.43 15.7 9700 173000 0.5 81.1 15.7 0
2 2 2 1 4 105 55 129 84 2 6 0 FALSE 11 0.12 12.2 7800 318000 0.4 127 19.6 0
2 1 2 2 4 109 67 129 84 11 2 0 FALSE 14 0.02 12 11500 179000 0.8 105 12.1 15
2 1 2 2 4 100 70 120 79 6 4 0 FALSE 140 0.14 12 8700 304000 0.4 79 6.3 7.5
9 9 9 9 122 60 129 84 FALSE 0.56 12.2 11100 241000 0.3 132 25.8 5
2 2 1 2 4 90 40 125 82 2 3 0 FALSE 168 0.3 9.1 11100 377000 1 96.5 25.1 5
2 1 1 2 8 100 60 124 81 23 1 0 FALSE 3 1.81 11.5 8000 359000 0.3 95 8.6 2.5
2 2 2 2 0 100 80 132 86 0 0 0 FALSE 40 0.1 9.9 11500 428000 0.4 119 27.4 12.5
2 2 2 2 0 90 52 116 77 0 0 0 FALSE 2 0.07 12 3900 213000 0.3 102 30.5 0
2 2 1 2 4 114 74 130 83 3 4 1 FALSE 543 1.16 9 17100 240000 0.6 72.5 13.2 60
4 12 5 FALSE 12.6 0
7 4 0 FALSE 13.3 0.5
1 0 0 FALSE 12.9 0.5
6 5 0 FALSE 12.9 0.4
3 2 0 FALSE 12.5 0.4
1 1 0 FALSE 13.3 0.7
1 3 0 FALSE 11.5 0.3
1 1 0 FALSE 13.1 0.3
3 1 0 FALSE 12.3 0.9
6 5 0 FALSE 8.5 0.6
5 2 0 FALSE 13.6 0.6
1 1 0 FALSE 14.7 0.6
3 5 0 FALSE 8.3 0.3
1 1 0 FALSE 12.4 0.4
3 2 0 FALSE 13.7 0.3
1 1 0 FALSE 11.7 0.5
4 2 0 FALSE 14 0.4
2 1 0 FALSE 13 0.5
0 0 0 FALSE 12 0.4
3 4 0 FALSE 13.7 0.5
2 1 0 FALSE 10.4 0.4
0 0 0 FALSE 13.8 0.4
6 3 0 FALSE 14 1
0 0 0 FALSE 13.1 0.5
1 1 0 FALSE 12.1 0.3
2 1 0 FALSE 12.8 0.7
1 1 0 FALSE 11.6 0.4
2 1 0 FALSE 11.3 0.4
5 1 0 FALSE 13.4 0.5
2 2 1 2 4 90 60 120 79 1 2 2 FALSE 0.17 12.5 5900 205000 0.4 57.9 6.4 15
1 2 1 1 12 99 53 131 85 1 27 1 TRUE 26 0.98 13.6 10900 143000 0.5 38.2 11.4 30
2 2 2 2 0 107 68 123 82 0 0 0 FALSE 269 0.13 10.2 22600 431000 0.4 63.4 6.3 20
2 2 2 2 0 90 60 132 86 5 2 0 FALSE 697 0.07 11.9 4600 38000 0.5 47.8 6.3 0
1 2 1 1 12 104 62 129 84 4 6 1 TRUE 75 0.07 12.2 9600 540000 0.5 133 22.6 15
2 2 2 2 0 104 62 128 83 0 0 0 FALSE 38 0.1 10.4 4700 336000 0.5 137 18.4 0
2 2 2 2 0 90 58 137 87 3 5 0 FALSE 586 0.04 12.2 6600 403000 0.6 84.7 7 0
2 2 2 2 0 94 52 132 86 1 1 0 FALSE 7 0.08 11.4 6800 79000 0.6 81 12.6 10
2 2 2 1 4 124 67 126 82 3 10 0 FALSE 535 0.13 13 11100 312000 0.5 74.2 6.3 0
2 2 2 2 0 96 50 130 83 2 2 0 FALSE 11 0.16 11.6 10000 220000 0.4 30.6 6.7 0
2 2 2 2 0 120 84 132 86 2 4 0 FALSE 86 0.04 12.3 15500 271000 0.7 85.7 12.6 30
2 2 2 2 0 125 70 132 86 0 0 0 FALSE 3 0.03 10.3 10100 325000 0.5 118 9.7 0
2 1 0 FALSE 12.9 14400 418000 0.4
0 0 0 FALSE 11.8 10200 153000 0.4
2 1 0 FALSE 10.9 10100 256000 0.3
2 1 0 FALSE 13.4 0.6
2 1 0 FALSE 13.8 0.4
1 1 0 FALSE 13 0.4
0 0 0 FALSE 11.8 0.5
4 2 0 FALSE 13.3 0.5
0 0 0 FALSE 11.7 0.6
1 2 0 FALSE 11.9 0.4
1 1 0 FALSE 11.7 0.4
2 2 2 2 0 120 78 3 2 0 FALSE 448 0.04 11.2 4300 281000 0.5 51 6.3 30
9 9 9 9 98 54 FALSE 542 1.68 7.6 3700 32000 0.5 31.5 6.4 0
2 2 2 1 4 100 64 1 6 0 FALSE 486 0.21 8.5 7200 565000 0.5 52.1 17.8 0
1 2 2 2 4 102 62 2 3 0 TRUE 108 0.06 11.5 5300 254000 0.4 108 16.3 20
2 1 1 1 12 119 64 25 10 1 FALSE 102 0.1 13 5000 304000 0.5 97.8 16.2 0
2 2 2 2 0 99 56 124 81 0 0 0 FALSE 362 0.14 10.8 6400 265000 0.5 102 14 5
2 2 2 2 0 104 60 135 85 0 0 0 FALSE 1 0.15 14.1 9400 348000 0.4 125 10.4 0
2 1 1 2 8 103 70 132 86 45 5 1 FALSE 133 0.22 11.3 6100 84000 0.4 42.1 5.9 7.5
2 2 2 1 4 112 62 128 83 2 16 0 FALSE 45 0.12 12 8800 297000 0.4 95.4 21.8 20
2 2 2 2 0 100 64 120 79 1 2 0 FALSE 36 0.11 11.4 7200 7000 0.4 86.2 6.3
2 2 1 2 4 100 70 131 85 5 1 1 FALSE 495 0.05 12.9 7400 431000 0.5 80 7.2 5
1 1 1 1 15 110 66 131 85 9 8 1 TRUE 386 0.05 10.2 8600 258000 124 16.8 15
2 2 2 2 0 130 100 135 85 0 0 0 FALSE 135 0.41 11.4 16900 43700 0.7 40
FALSE 0.02
FALSE 12.83
FALSE
FALSE
FALSE
FALSE
FALSE 12.86
FALSE
FALSE 4.22
FALSE
FALSE
FALSE
FALSE 4.01
FALSE 12.95
FALSE
FALSE
FALSE
FALSE 3.25
FALSE 6.45
FALSE 3.42
FALSE
FALSE
FALSE
FALSE
FALSE
FALSE 6.59
FALSE 4.7
FALSE
FALSE
FALSE
FALSE
FALSE
FALSE 2.46
FALSE
FALSE 0.03
FALSE
FALSE
2 2 2 2 0 110 62 129 84 0 0 0 FALSE 57 0.14 11.7 8600 320000 0.5 105 14.9 0
2 2 2 2 0 97 59 0 0 0 FALSE 118 0.07 11.9 5000 258000 0.5 87.9 6.3 0
2 2 2 2 0 100 50 132 84 5 2 0 FALSE 185 0.5 12.7 62000 311000 0.5 34.9 6.4 40
2 2 2 2 0 110 77 122 80 0 0 0 FALSE 418 0.11 11.9 10300 166000 0.6 94.7 20.9 15
2 1 2 2 4 103 66 126 82 7 3 0 FALSE 412 0.15 12.7 8600 321000 0.5 84 11.5 10
2 2 1 1 8 116 90 131 85 4 7 1 FALSE 105 0.07 12.5 10400 349000 0.5 146 15.9 2.5
2 2 2 2 0 100 60 132 86 0 0 0 FALSE 107 0.02 10.3 5800 249000 0.6 107 8.5 0
2 2 2 1 4 109 60 132 86 3 105 0 FALSE 3 0.12 12.2 4800 218000 0.6 85.2 10.1 0
2 2 2 2 0 102 66 127 83 0 0 0 FALSE 13 0.14 12.7 9000 429000 0.4 96.1 7.1 30
2 1 1 1 12 94 54 131 85 13 15 2 FALSE 803 0.6 9.3 2900 357000 0.5 98.2 18.1 0
9 9 9 9 116 70 132 86 5 FALSE 500 9.8 8000 149000 0.7 67.8 11.7 0
FALSE
FALSE 0.5
FALSE
2 2 2 2 0 98 44 132 86 3 2 0 FALSE 16 0.02 9.7 3600 192000 0.8 56.7 6.3 5
2 2 2 2 0 95 63 132 84 2 2 0 FALSE 340 0.63 9.6 3700 135000 0.6 23.2 6.4 60
2 2 2 2 0 97 67 128 83 0 0 0 FALSE 49 0.14 12.5 6800 239000 0.5 102 19.3 0
dur immuno mmf hcq azathio cyclo others
60 1 FALSE TRUE TRUE FALSE FALSE
6 0 FALSE FALSE FALSE FALSE FALSE
60 1 TRUE TRUE FALSE TRUE FALSE
36 1 TRUE TRUE FALSE FALSE FALSE
12 1 FALSE TRUE FALSE TRUE FALSE
24 1 TRUE TRUE FALSE FALSE FALSE
7 1 TRUE TRUE FALSE FALSE FALSE
2 1 FALSE TRUE FALSE FALSE FALSE
1 0 FALSE FALSE FALSE FALSE FALSE
0 0 FALSE FALSE FALSE FALSE FALSE
0 0 FALSE FALSE FALSE FALSE FALSE
27 1 FALSE TRUE FALSE FALSE TRUE
0 0 FALSE FALSE FALSE FALSE FALSE
9 0 FALSE TRUE FALSE FALSE FALSE
3 1 FALSE TRUE TRUE TRUE FALSE
6 0 FALSE FALSE FALSE FALSE FALSE
1 1 FALSE TRUE FALSE FALSE FALSE
17 1 TRUE TRUE FALSE FALSE FALSE
36 1 TRUE TRUE FALSE FALSE TRUE
24 1 TRUE TRUE FALSE FALSE FALSE
60 1 TRUE TRUE FALSE FALSE FALSE
48 2 TRUE TRUE FALSE TRUE TRUE
24 1 FALSE TRUE TRUE FALSE FALSE
0 0 FALSE FALSE FALSE FALSE FALSE
23 1 FALSE TRUE TRUE FALSE FALSE
12 1 FALSE TRUE FALSE FALSE FALSE
24 1 TRUE FALSE FALSE FALSE FALSE
36 1 TRUE TRUE FALSE FALSE FALSE
12 1 TRUE TRUE FALSE FALSE FALSE
8 1 TRUE TRUE FALSE FALSE FALSE
4 1 FALSE TRUE FALSE FALSE FALSE
18 1 TRUE TRUE FALSE FALSE FALSE
72 1 FALSE TRUE TRUE FALSE FALSE
17 1 FALSE TRUE TRUE FALSE FALSE
17 1 TRUE TRUE FALSE FALSE FALSE
26 1 TRUE TRUE FALSE FALSE FALSE
4 1 FALSE TRUE TRUE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
21 1 FALSE TRUE FALSE FALSE FALSE
3 1 FALSE TRUE FALSE FALSE FALSE
1 1 FALSE TRUE FALSE FALSE FALSE
0 0 FALSE FALSE FALSE FALSE FALSE
2 1 FALSE TRUE FALSE FALSE FALSE
0 0 FALSE FALSE FALSE FALSE FALSE
18 1 FALSE TRUE FALSE FALSE FALSE
8 1 FALSE TRUE FALSE FALSE FALSE
0 1 TRUE FALSE FALSE FALSE FALSE
0 0 FALSE FALSE FALSE FALSE FALSE
74 1 FALSE TRUE TRUE FALSE FALSE
84 0 FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
40 1 FALSE TRUE FALSE FALSE FALSE
0 0 FALSE FALSE FALSE FALSE FALSE
14 1 FALSE TRUE FALSE FALSE FALSE
4 1 FALSE TRUE FALSE FALSE FALSE
10 1 FALSE TRUE FALSE FALSE FALSE
23 1 FALSE TRUE FALSE FALSE FALSE
13 1 TRUE TRUE TRUE FALSE FALSE
51 1 FALSE TRUE FALSE FALSE FALSE
6 1 FALSE TRUE FALSE FALSE FALSE
1 0 FALSE FALSE FALSE FALSE FALSE
24 1 FALSE TRUE FALSE FALSE FALSE
4 1 FALSE TRUE FALSE FALSE FALSE
1 1 FALSE TRUE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
18 1 FALSE TRUE FALSE FALSE FALSE
0 1 FALSE TRUE FALSE FALSE FALSE
1 1 FALSE TRUE FALSE FALSE FALSE
17 1 FALSE TRUE TRUE FALSE FALSE
7 1 FALSE TRUE FALSE FALSE FALSE
17 1 FALSE TRUE FALSE FALSE FALSE
60 1 FALSE TRUE FALSE FALSE FALSE
22 1 FALSE TRUE FALSE FALSE FALSE
1 1 FALSE TRUE FALSE FALSE FALSE
0 1 FALSE TRUE TRUE FALSE FALSE
29 1 FALSE TRUE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
FALSE FALSE FALSE FALSE FALSE
34 1 TRUE TRUE FALSE FALSE FALSE
1 0 FALSE FALSE FALSE FALSE FALSE
20 1 TRUE TRUE FALSE FALSE FALSE
